Abstract
This narrative review summarises the benefits, risks and appropriate use of acid-suppressing drugs (ASDs), proton pump inhibitors and histamine-2 receptor antagonists, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences. It focuses on current controversies on the potential of ASDs to contribute to infections—bacterial, parasitic, fungal, protozoan and viral, particularly in the elderly, comprehensively and critically discusses the growing body of observational literature linking ASD use to a variety of enteric, respiratory, skin and systemic infectious diseases and complications (Clostridium difficile diarrhoea, pneumonia, spontaneous bacterial peritonitis, septicaemia and other). The proposed pathogenic mechanisms of ASD-associated infections (related and unrelated to the inhibition of gastric acid secretion, alterations of the gut microbiome and immunity), and drug-drug interactions are also described. Both probiotics use and correcting vitamin D status may have a significant protective effect decreasing the incidence of ASD-associated infections, especially in the elderly. Despite the limitations of the existing data, the importance of individualised therapy and caution in long-term ASD use considering the balance of benefits and potential harms, factors that may predispose to and actions that may prevent/attenuate adverse effects is evident. A six-step practical algorithm for ASD therapy based on the best available evidence is presented.
Similar content being viewed by others
Acid-suppressing drugs (ASDs), one of the most commonly prescribed and relatively safe classes of medications, through a variety of different mechanisms (alterations of important defense systems including the gut microbiome and immunity) might predispose to the development of infectious diseases, particularly in the elderly. |
The existing controversies on the associations between ASDs and a variety of infections (bacterial, parasitic, fungal, protozoan and viral), proposed pathogenic mechanisms and drug-drug interactions are comprehensively reviewed. |
The importance of individualized evidence-based therapy with a proper risk/benefit assessment is emphasized, actions that may prevent adverse effects (avoidance inappropriate prescribing, probiotics use and correcting vitamin D status) are discussed, and a practical algorithm for ASD therapy is presented. |
1 Introduction
Over the last decades, gastric acid-suppressing drugs (ASDs), histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), revolutionised the treatment and prevention of acid-related diseases and currently are among the most commonly prescribed medications worldwide. These agents are highly effective for treating acid-mediated disorders of the upper digestive tract (peptic ulcers, eradication of Helicobacter pylori infection, acute nonvariceal bleeding, gastro-esophageal reflux disease (GERD), erosive esophagitis), prevention of nonsteroidal anti-inflammatory drug (NSAID)-related injury and stress ulcers [1–13]. ASDs are generally well tolerated and considered to have a safe profile [14–17]. However, emerging data indicate that use of ASDs, especially in the elderly in presence of comorbidities and/or co-medications, may be associated with serious adverse health effects including bacterial infections such as Clostridium difficile infection (CDI), Salmonella, Campylobacter, pneumonia, and others, all of which increase morbidity and mortality.
As the development of infections depends on a plethora of factors affecting the complex balance between immune defences and flora, any medication likely to modify this balance might be involved in occurrence of infections. Therefore, clinical decision-making, assessing and balancing the efficacy, safety and tolerability [18] as well as considering ethical dilemmas [19] of prescribing medications for an elderly patient with respect to co-existing comorbidities and polypharmacy has become challenging and complex. Moreover, while some recent publications emphasised the underuse of gastroprotective agents, especially in older patients receiving NSAIDs [7, 20, 21], others highlighted the over-utilisation of PPIs [22–27]. It has been estimated that inappropriate use of PPIs, particularly in the elderly, may exceed 75% [26, 28, 29].
The absence of unambiguous guidelines, controversial reports and recommendations in the existing scientific literature leaves the prescribing physician trying to choose “the right medication for the right patient” sometimes between Scylla and Charybdis.
This narrative review attempts to provide a comprehensive insight into the main issues and uncertainties associated with the potential infectious risks of use of ASDs, especially in an elderly often multimorbid and frail patient within the context of overall clinical benefits and harms, advocating a rationale balanced and individualised approach aimed to minimise any serious adverse consequences.
2 Methods of Literature Search
We performed an updated MEDLINE/PubMed search focusing mainly on publications from 1 January 2000 to 31 December 2016, and selected appropriate articles for discussion. In order to give the reader, as much as possible, a complete review of the topic, we have widened the spectrum of clinical conditions included.
3 General Considerations
Proton pump inhibitors covalently bind with sulfhydryl groups of the cysteine residues of the H+/K+ adenosine triphosphatase (H+/ K+ ATPase) on the plasma membrane of the gastric parietal cell irreversibly blocking the final step in acid secretion in response to all modes of stimulation—muscarinergic, gastrinergic and histaminergic [30–32], while H2RAs block only one—the histaminergic—of the three pathways in acid secretion. Therefore, PPIs are significantly more effective, faster and longer-acting suppressors of gastric acid secretion than the H2RAs. PPIs, despite the individual differences, are similar with respect to half-lives, time to maximum plasma concentration and safety [33]. All PPIs, except tenatoprazole, undergo hepatic metabolism via the CYP isoforms CYP2C19 and CYP3A4, and genetic polymorphism in CYP2C19 affects the metabolism and effectiveness of omeprazole and lansoprazole but not esomeprazole or rabeprazole [34–37]. Because omeprazole (but not pantoprazole) is a metabolism-dependent inhibitor of CYP2C19, it causes clinically significant interaction with clopidogrel [38].
The frequency of adverse reactions from H2RAs was reported to be similar to that for placebo [39, 40]. However, cytopenias and leukocytosis [41], nephrotoxicity and hepatotoxicity [42], as well as drug interactions [43–45] have been described.
4 Acid-Suppressing Therapy and Risk of Enteric Infections
Gastroenteritis is a common infectious disease requiring hospitalisation of approximately 1% of people ≥65 years of age annually [46]. The incidence of diarrhoea, the most common adverse effect from long-term PPI use and the most frequent indication for discontinuing PPI therapy, ranges from 3.7 to 4.1% [47–50]. In comparison, antibiotic-associated diarrhoea occurs in 5–39% [51]. The most likely causes of infectious diarrhoea include C. difficile, Campylobacter jejeuni, Salmonella spp., C. perfringens, Staphylococcus aureus, Klebsiella oxytoca, enterotoxic Escherichia coli, and viruses, although in many cases no infectious agent is ever determined [52–54]. C. difficile infection (CDI) is the leading cause of antibiotic-associated diarrhoea and accounts for 15–39% of cases [55–57]. The potential of ASDs to increase enteric infections, particularly in the elderly, has been recognised [58, 59].
4.1 Clostridium difficile Infection (CDI)
In the last decade, CDI, the most common of healthcare-associated infections [60], has become increasingly prevalent and severe [61–71]. Currently, it often (up to 75% of cases) occurs in the community or nursing homes (approximately in one-quarter of all CDI) [65, 72, 73], is not associated with healthcare/hospital exposure in up to one-third [73], and is unrelated to antibiotic use [74]. Most importantly, the incidence of CDI is disproportionately high among older patients [72, 75–78], especially among the most vulnerable and frail population of long-term residential care facilities (RCF) [73, 79–81]. The elderly with CDI often develop severe complications [82, 83] and persons aged ≥65 years account for up to 90% of CDI-related mortality within 30 days [65]. Current antimicrobial therapies for CDI still have relapse rates of 15–30% [84–86].
C. difficile, a Gram-positive, anaerobic, spore-forming, toxin-producing bacillus, is acquired by the ingestion of spores via the fecal-oral route. Pathogenesis of CDI involves a complex interplay of three key mechanisms: (1) C. difficile toxin production, (2) disruption of the gut microbiota and (3) host factors. Although antibiotics are currently recognised as a major risk factor for acquiring CDI due to their effect on the normal structure of the indigenous gut microbiota [55, 87–92], emerging data indicate that the prevalence of CDI cannot be fully explained by antimicrobial exposure, suggesting that other variables—comorbidities and medications affecting both the microbiota and the immunological status—may substantially contribute to the burden of CDI, particularly in the elderly population. Age is recognised as a major risk factor for the development of CDI with disease incidence and severity escalating as age increases [93].
Numerous epidemiological observational studies and meta-analyses [55, 74, 89, 92, 94–120] showed a statistically significant increase in both nosocomial and community-acquired CDI among patients taking PPIs or H2RAs (Table 1). In PPI users, odds ratio (OR) [or relative risk (RR)] ranges between 1.74 [46, 103]–1.90 [118]–1.96 [121]–2.15 [122]–2.90 [117]–3.3 [115] and 3.60 [97], in H2RA users between 1.40 [121]–1.44 [107] and 1.50 [123]. The pooled estimates showed a 1.3- to 3.3-fold increase in risk for CDI with ASD therapy [103, 104, 106, 115]; a lesser increase in risk with the use of H2RAs compared to PPIs as it was reported in the majority of studies may indicate a correlation with the degree of acid suppression [101, 119]. The association between ASDs and CDI appeared to be the level of acid suppression [119, 122], and is duration dependent [111]. Interestingly, in the paediatric population, CDI risk was associated with H2RAs (OR 4.6) but not PPIs use [124]. In one study, the proportion of cases of CDI among PPI users was as high as 65% [104]; others found that 31% of CDI patients without antibiotic exposure received PPIs [74]. In critically ill medical patients, risk of CDI associated with PPI therapy (OR 3.11) was comparable to the risk associated with the use of fluoroquinolones or third-generation cephalosporins [125]. Continuous PPI use (on average observed in 40–60% of CDI patients), similar to antibiotic re-exposure, was also associated with an increased risk for recurrent CDI [96, 100, 114] with an OR of 2.51 [103]–4.17 [96]. Among patients with extra-intestinal CDI, 50% used PPIs [126].
Importantly, PPIs co-administered with an antibiotic increase the risk of CDI approximately two-fold above that observed with PPI alone [103, 127]. The absolute risk of CDI associated with H2RAs was highest in hospitalised patients receiving antibiotics with an estimated number-needed-to-harm (NNH) of 58 at 2 weeks compared to 425 not receiving antibiotics [107]. On the other hand, ASDs (taken by two-thirds of CDI in-patients) did not worsen clinical response or recurrence rate when used concurrently with vancomycin or fidaxomicin, and it is recommended to continue PPI or H2RA treatment in CDI patients with risk of gastrointestinal bleed or GERD [128].
The US Food and Drug Administration (FDA) required that the package insert for PPIs contain a warning that PPIs may increase the risk of CDI. Noteworthy, even in healthy subjects, daily acid suppression affects gut microbiota composition [129], and these microbiota shifts are associated with functional changes that could cause bacterial overgrowth [130] and pathogen colonisation including C. difficile [131].
However, the subject remains controversial. An increased risk of CDI in PPI users has not been confirmed by some researchers [132–135], especially after adjusting for coexisting conditions [108, 133, 136–141]. No increase in the number of patients with CDI following total gastrectomy was reported [138]. Because in the elderly the prevalence of gastric hypochlorhydria is high, ASDs may not demonstrate an additional to antibiotic use risk of CDI [135]. A case–effect relationship between PPI use and CDI has not been supported by a meta-analysis which included 37 case–control and 14 cohort studies [108]; the authors estimated that in the general population taking PPIs the risk of CDI is very low; NNH of 3925 at 1 year. A meta-analysis on CDI in H2RA users (33 studies) by the same group reported NNH of 58 (95% CI 37–115) among patients receiving antibiotics and of 425 (95% CI 267–848) among patients not receiving antibiotics [107].
A recent review concluded that the influence of acid suppression in CDI remains uncertain [93], while an expert panel of infectious disease specialists agreed that PPIs are an important risk factor [66]. The newest position statement by the Sociedad Española de Patologia Digestiva indicates that the association between PPIs and CDI is mild to moderate [142]. Obviously, for a more definitive answer a prospective randomised controlled trial is needed but it would be difficult to conduct (need of a large sample size, diagnostic suspicion bias, lack of a pharmaceutical sponsor). Meanwhile, despite the limitations of observational studies, the potential association of ASDs with CDI should not be ignored [114] and clinicians should put more attention in adhering to indications for ASDs use.
4.2 Other Enteric Bacterial Infections
Use of ASDs has also been associated with an increased risk of enteric infections [121], especially Salmonella spp. and Campylobacter spp. [101, 143–148]. Five case-controlled studies have observed an association between ASDs and Salmonella infection with ORs ranging from 1.84 to 11.2 [146, 147, 149–152]. In PPIs users, the OR of infection caused by Salmonella ranged 2.09–8.3, by Campylobacter 1.7–11.7 [101, 145–147, 149, 150]. During an outbreak of salmonellosis, residents of a long-term care facility treated with ASDs were eight times more likely to develop the infection [153]. An 11.7-fold increase in the risk of gastroenteritis due to Campylobacter spp. was reported among 211 patients (aged >45 years) receiving omeprazole in the month before infection but not in former users, and no association with H2RAs was observed [145]. The risk of Salmonella- and Campylobacter-induced gastroenteritis (n = 6414 patients) was significantly associated with use of PPIs (RR 2.9) but not H2RAs [146]. In a meta-analysis (6 studies, 11280 patients) the pooled OR of enteric infections in ASD users was 2.55, with a greater association for PPIs (OR 3.33) compared to H2RAs (OR 2.03) [121]. Similarly, a recent nested case–control study of a national database on hospitalised population (14,736 case patients and 58,944 controls) reported a significant association between occurrence of nontyphoid salmonellosis and PPIs (total OR 2.09, in current users OR 5.39) or H2RAs (OR 1.84) therapy [147]. These data are in line with many previous observations of increased occurrence of non-typhoid salmonellosis in patients with reduced gastric acid secretion [154–156] and following gastric resection for peptic ulcer disease or gastric malignancy [155, 157–160]. The protective role of gastric juice against salmonella infections was also demonstrated in mice [161]. In adult volunteers, two strains of C. jejuni produced a higher rate of infection and illness when ingested with sodium bicarbonate indicating the protective role of gastric acid [162].
However, a retrospective analysis of almost 2 million individuals (about 360,000 were prescribed a PPI) after adjusting for confounding factors and eliminating the effect of time intervals did not find that PPIs increased the rate of Campylobacter and Salmonella infections [163]. The authors concluded that patients prescribed PPIs had greater underlying predisposing risks for gastrointestinal infections with a 3.1–6.9 times higher rate of these infections compared to non-PPI users even before PPI treatment started [163]. Similarly, observations from the SOPRAN and LOTUS studies did not indicate any difference in the incidence of enteric infections between the treatment groups [15]. The conflicting results may be, at least partially, related to selection bias [164]. Of note, it was shown that ASDs increased the susceptibility to Salmonella and Campylobacter infections mainly in current users and within 1–3 months after therapy ended [145–147, 149], while no association was seen when the incidence of enteric infection was compared in PPIs users 12 months before and after the event [149, 163].
In the last decade, an increased incidence of human listeriosis, a rare but dangerous food-borne disease that accounts for 20–30% of food-borne deaths [165–168], has been reported among the elderly, especially with reduced immunocompetency (cancer, diabetes, immunosuppressive therapy) and/or ASD users, in UK [169], Austria [170], Denmark [171], Spain [168] and Germany [172], as well as in North America, Japan [166] and Taiwan [173]. Moreover, in England, prescribing patterns for PPIs closely correlated with the incidence of Listeria monocytogenes bacteraemia [169]. Previous case-controlled studies found that H2RAs and antacid use was associated with outbreaks of hospital-acquired listeriosis [174, 175]. Other researchers demonstrated that patients on long-term H2RA therapy have an increased prevalence of L. monocytogenes in the feces (20 vs. 2.1% in controls), but none of them developed listeriosis [176]. Cimetidine significantly lowered the infective dose of virulent L. monocytogenes in rats [177], although this Gram-positive bacillus and facultative intracellular organism can survive the body’s natural defences within the digestive tract, including acid conditions of the stomach and bile acids [167, 178–181].
Use of H2RAs [182] or antacids [183] has also been linked to development of acute brucellosis. Because gastric juice is lethal to Brucella spp. in vitro [183, 184] drug-induced hypochlorhydria may facilitate the transit of microorganisms and disease. Lowering suppressor/cytotoxic T lymphocyte counts [185] by cimetidine may contribute to this adverse effect [186].
A case of septicaemia due to Yersinia enterocolitica (primarily a gastrointestinal Gram-negative bacilli transmitted through consumption of contaminated food or water) in a haemodialised patient receiving omeprazole has been reported [187]; raised intra-intestinal pH and increased intraluminal iron load were suggested as the main contributing factors for the infection.
Shigella spp. are acid-resistant organisms [188] and gastric hypochlorhydria does not influence the susceptibility to this infection [189]. However, in volunteers, pretreatment with sodium bicarbonate increased the isolation of the vaccine strain of Shigella flexneri in stools three-fold [190] indicating the potential role of alteration of gastric pH and/or facilitating gastric emptying on bacterial survival.
4.3 Gastric and Small Intestinal Bacterial Overgrowth (SIBO)
Acid-suppressing drug therapy is known to be associated with gastric and duodenal bacterial overgrowth. Following both H2RAs [191–195] and PPIs [195–200] high intragastric non-H. pylori bacterial counts (in both the gastric juice and mucosa) and rises in potentially carcinogenic nitrite and N-nitrosamine concentrations [193, 194, 196] were observed in several studies. The bacterial overgrowth correlated with the intragastric pH [199, 201], daily duration and degree of hypochlorhydria [198, 199] and increases in the concentration of unconjugated bile acids [198, 202]. It was suggested that the reflux of toxic unconjugated bile acids [203] into the esophagus may cause mucosal injury even in ASD users [156]. In ASD users, the overgrowth was predominantly of Gram-positive organisms, resembling that found in the mouth and oropharynx [199]. Use of PPIs or H2RAs in H. pylori-positive subjects resulted in higher intragastric pH, greater non-H. pylori bacterial colonisation, increased cytokine and N-nitrosamine levels and higher risk of atrophic gastritis [204, 205].
However, in other studies, no significant changes in intragastric bacterial counts or in bacterial species and N-nitroso-compound levels were found after cimetidine [206] and no increases in the concentration of nitrates or nitritis were noted in healthy volunteers receiving omeprazole for 2 weeks [197, 207].
Numerous reports have found an association between ASDs and SIBO. It has been documented in H2RA users [191, 208, 209] and following PPI therapy [138, 208–222]. SIBO incidence was considerably higher in patients treated with PPIs compared with H2RAs [210, 223]. These observations are in line with an increase in number of subjects with SIBO among patients with atrophic gastritis [211] and after total gastrectomy [224, 225]. The pooled (11 studies, n = 3134) OR for SIBO in PPI users versus nonusers was 2.28 [222]; the association was highly significant with OR of 7.59 only when the diagnosis was made by an accurate test such as duodenal or jejunal aspirate culture but not glucose hydrogen breath test (GHBT). Breath tests based on bacterial metabolism of various substances may produce false results [226], especially in the elderly [208, 211, 227]. Indeed, in two large studies PPI usage was not associated with the presence of SIBO as determined by GHBT (n = 1191) [228] or a positive D-xylose breath test (n = 932) [229], and one recent small study (n = 94) failed to detect an association between PPIs or H2RAs use and SIBO assessed by the lactulose hydrogen breath test [230]. The newest and largest study on this topic [231] once again confirmed that impairment of acid barrier by current PPI therapy is an important pathomechanistic pathway for the development of SIBO (OR 1.43); a potential risk of SIBO in chronic PPI users has also been observed in children [232].
ASD-related SIBO is of clinical significance, as both SIBO and reduced gastrointestinal motility (which is also an independent risk factor for development of SIBO [217, 233]), are relatively frequent, especially in older adults, may cause malabsorption and are linked to many diseases [138], including diabetes mellitus [234], non-alcoholic fatty liver disease [235, 236], liver cirrhosis [209], chronic kidney disease (CKD) [237], hypothyroidism [238], autoimmune diseases [239], obesity, irritable bowel syndrome [240, 241], gastric bypass surgery [242], cholecystectomy [243] and chronic pancreatitis [244, 245]. Because ASDs may be one of several factors contributing to SIBO and its consequences prescribing of ASDs in individuals with these conditions needs to be carefully considered.
4.4 Spontaneous Bacterial Peritonitis (SBP)
Patients with liver cirrhosis are immunocompromised and particularly prone to developing spontaneous bacterial infections often with serious complications (acute-on-chronic liver failure, renal failure, and shock) resulting in high mortality rates (30–50%) [246–249]. Because of the high prevalence of bleeding gastroduodenal ulcers [250, 251] with high mortality [252] these patients are often prescribed ASDs, although the evidence of their protective efficacy is poor [253]. Patients with cirrhosis and ascites receiving ASDs were found to be at a higher risk of SBP, overall bacterial infection [216, 254–263] and mortality [264]. In cirrhotic patients with ascites treated with PPIs the OR for developing SBP ranged between 1.40 [258] and 4.31 [254]. Meta-analyses found pooled OR for SBP for PPIs users of 1.72 [265]−2.11 [266]−2.17 [267]−2.77 [259, 268]−3.15 [269], and for HR2A users of 1.71 [269]−2.62 [259]; an OR of 1.98 for the overall risk of bacterial infection in PPIs users was reported [267]. The risk of SBP increased significantly with longer ASD use [259, 270]. A large case–control study revealed that use of PPIs in patients with cirrhosis (n = 1166) increases the risk of development of hepatic encephalopathy in a dose-dependent fashion [271].
However, some researchers did not confirm an increased risk of SBP in users of PPIs [216, 272, 273] or H2RAs [263] and did not observe a link between PPIs and bacterial infections, prognosis and mortality in cirrhotic patients [216, 274, 275]. A recent meta-analysis (10 case–control and 6 cohort studies, 8145 patients) showed that the association of PPIs with SBP was significant only in case–control studies (OR 2.97, 95% CI 2.06–4.26) but not in cohort studies (OR 1.18, 95% CI 0.99–1.14) and was not associated with increases in 30-day mortality [266]. Of practical importance, clinical trials [276–278] and current guidelines [279] do not support PPI use for prophylaxis of portal hypertension-related bleeding and recommend only a short-course of PPI post-endoscopic variceal ligation if ulcer healing is a concern [276, 279]. Of note, in patients with liver cirrhosis the prevalence of peptic ulcers ranges between 5 and 28% [253, 277], while inappropriate prescription of PPIs was found in 34–60% of cirrhotic patients [256, 257, 274, 278, 280–282]. Interestingly, in patients with CKD undergoing chronic peritoneal dialysis, the association of ASDs with enteric peritonitis (RR 1.65) and infectious mortality was more pronounced in H2RA users but less consistent among those treated with PPIs [283].
4.5 Liver Abscess and Acute Cholangitis
Use of PPIs was shown to be associated with an increased risk of cryptogenic liver abscess: OR was 4.7 for current users and 2.9 for the past users 31–90 days [284]. PPI therapy was also related to a higher incidence of cholangitis associated with increased number and broader spectrum (oropharyngeal flora) of pathogens in the biliary tract [285].
4.6 Enteric Parasitic Infections
Amongst protozoan parasites, Giardia lamblia is one the commonest etiological agents of acute usually self-limited diarrhoea worldwide (especially in developing countries), although in some patients it may become chronic with serious long-term effects [286–289]. G. lamblia is acid-sensitive. Hypochlorhydria was found in 54% of patients with intestinal giardiasis [290, 291] and associated with more severe symptoms. As survival of the parasite in the stomach requires reduced acidity, the infection, not surprisingly, is associated with chronic atrophic gastritis [292, 293] but gastric infection is rare (less than 100 cases reported in the literature [294]). In case reports, giardiasis was associated with chronic use of PPIs [175, 295–297] and ranitidine [298] as well as following gastric surgery [299]. On the other hand, a recent experimental study demonstrated that in vitro omeprazole, by inhibiting giardial triosephosphate isomerase, is effective against G. lamblia, including drug-resistant strains [300].
Strongyloidiasis, a parasitic infection endemic in tropical and subtropical regions [301–304] and observed in immunosuppressed individuals [305, 306], is also associated with hypochlorhydria [291, 307]. Gastric strongyloidiasis has been diagnosed in patients with hypochlorhydria [156, 308] and in a woman receiving H2RAs and PPIs for 2 years [309]. Opportunistic Strongyloides stercoralis hyperinfection has been reported following cimetidine therapy in immunosuppressed patients [308, 310, 311] but there were no publications of this in PPI users [294]. In one study, gastric acid levels were not associated with giardiasis or strongyloidiasis [189].
Experimental studies showed that rats pretreated with cimetidine can be infected orally with Entamoeba histolytica [312] indicating the protective effect of gastric acid against this protozoa. Artificial gastric fluid, containing 0.6% hydrochloric acid (pH 1.8) and 0.5% pepsin, but not artificial intestinal fluid, contributes to enhancing excystation for Entamoeba infection [313].
Interestingly, recent studies revealed that many widespread bacteria (Salmonella enteric, E. coli, Y. enterocolitica, L. monocytogenes) survive inside cysts of the ubiquitous amoeba Acanthamoeba castellanii, even when exposed to highly acidic conditions (pH 0.2) or antibiotics [314, 315]. An increase in acid tolerance of C. jejuni when co-incubated with amoeba was also reported [316]. These findings suggest the important role of protozoa and their cysts in the epidemiology of food-borne bacteria and the possible ways of ASDs involvement.
5 Respiratory Infections, Bacterial Pneumonia
Pneumonia, one of the most common infectious diseases, is a leading cause of morbidity and mortality in the elderly [317–325]. Evidence is accumulating on an increased risk of both community-acquired respiratory infections and nosocomial pneumonia in patients receiving ASDs, although the results are mixed. Subjects using ASDs compared to non-users, 2.3 times more often experienced respiratory infections, 3.7 times more often visited a physician for an infection and 4.2 times more often received antibiotics [326]. The OR for pneumonia ranged in patients taking PPIs between 1.27 [327]–1.3 [328]−1.5 [329]–1.89 [330], and in patients taking HR2As between 1.22 [331]–1.30 [332]–1.63 [330]; a dose-dependent association with PPIs was reported by some [330] but not all [329] researchers. In a meta-analysis of 33 studies, which included 6,351,656 participants, the pooled OR was 1.49 and the risk was reported to be higher during the first month of PPI therapy (OR 2.10) [333]. The association was particularly strong within a week (OR 5.0 [329]–3.79 [334]) or even the first 2 days (OR 6.53) [334] after PPI initiation, but declined over time [326, 329, 334] and was not significant for longer-term therapy [334]. The risk for pneumonia in users of ASDs was higher among patients with chronic obstructive airway disease (COPD) (OR 1.76 with PPIs, OR 1.25 with H2RAs [335], CKD (OR 2.21 with PPIs [336]), stroke [337] (OR 1.44 [338]–2.07 [339]–2.7 [340]), and non-traumatic intracranial haemorrhage (OR 1.61 [338]); the association was not significant for HR2As in stroke patients [338, 340].
Other investigators, however, reported no association between H2RAs therapy and pneumonia [329], as well as between PPIs and respiratory infections [341] (Table 1) and between PPIs and occurrence of pneumonia in COPD patients [335]. One meta-analysis (31 clinical trials) found that esomeprazole use did not increase the risk of community-acquired respiratory tract infection including pneumonia [342]; this conclusion has been recently confirmed in a report based on 24 randomised controlled trials (RCTs) by the same authors [343]. In some studies [344], ASDs have been found to significantly increase the risk of recurrent pneumonia in the elderly (OR 2.1), whereas in other reports the risk was higher among younger PPI users [329] and not obvious in individuals >70 years old [335]. Moreover, in a study based on medical record review (vs. only administrative records in most of other studies) of community-dwelling adults aged 65–94 years and controlling for confounding factors, neither PPI nor H2RA use increased pneumonia risk [345]. In patients with acute stroke, no difference in the incidence of pneumonia between PPI and H2RA users was reported in one study [346], whereas another found that in users of PPIs compared to H2RAs the relative risk of pneumonia was 1.69 [339]. Some observational studies concluded that PPIs do not increase the risk of nosocomial pneumonia, and, in contrast, reduce the risk of aspiration pneumonia in patients with a gastric tube in place [14, 347]. Of note, usefulness of ASDs in the management of GERD-related chronic cough and asthma has been described [348–351], and no difference in the incidence of lower respiratory tract infections was seen when patients treated with PPIs or anti-reflux surgery were compared [15]. The position statement by the Canadian Association of Gastroenterology [352] emphasised that the risk-to-benefit ratio appears to be largely in favour of using ASDs for conditions in which efficacy has been demonstrated.
In the setting of stress ulcer prophylaxis, the data on ASD-related pneumonia remain conflicting and require special consideration. In an intensive care unit (ICU), stress ulcer bleeding is a rare (1–6%) but severe complication (mortality 40–50%), therefore, the majority of these patients receive H2RAs or PPIs [353–355]. In a large European study, stress ulcer prophylaxis has been recognised as an independent risk factor of ICU-acquired infections among which pneumonia accounted for more than 50% [356]. Older studies indicated that prophylaxis with H2RAs is associated with an increase in the incidence of pneumonia as compared with placebo or sucralfate treatment [354, 357–359]. The risk of developing pneumonia in H2RA-treated patients was 1.3 [332] to 2 [353, 357] times higher than in the patients receiving sucralfate, which does not raise gastric pH. No difference in the rates of ventilator-associated pneumonia was observed with these two drugs in a randomised blinded placebo-controlled trial [360]. One retrospective study showed a significant association of PPIs with pneumonia only by univariate but not by multivariate analysis [125]. A PCT found a strong increase in ventilator-associated pneumonia among the PPI users compared to those receiving placebo (36.4 vs. 14.1%) [361]. The superiority of PPIs over H2RA for stress ulcer prophylaxis in patients with severe sepsis or septic shock who require mechanical ventilation has not been supported in one study [362]. However, recent meta-analyses demonstrated that in critically ill patients, PPIs were more clinically and cost effective than H2RAs in preventing upper gastrointestinal bleeding without affecting the rates of nosocomial pneumonia, length of ICU stay or mortality [4, 355, 363, 364]. It is evident from the existing data that the role of ASDs as a risk factor for community-acquired and nosocomial pneumonia is still unclear but remains likely.
6 Septicaemia
In the elderly, bloodstream infections are common and often fatal [365–367]. Reports implying an increased susceptibility to septicaemia associated with ASDs are scant and conflicting. In a randomised trial of critically ill trauma patients, ranitidine use compared with sucralfate was associated with a significant increase in overall infectious complications (OR 1.5), including bacteraemia (46.9%), pneumonia (25.0%) and catheter-related infections (19.8%) [332]; the number of infectious complications per patient averaged 2.6 and 1.1 in those receiving ranitidine and sucralfate, respectively. The multiple sites of infectious complications may suggest a potential immunosuppressive effect of ranitidine. Severe postoperative systemic infection after technically uncomplicated gastric resection was observed in two patients (one died) receiving prolonged omeprazole treatment preoperatively and without perioperative antibiotic prophylaxis [368]. A recent international survey (11 countries) found that most ICU units are using stress ulcer prophylaxis with PPIs (66%) or H2RAs (31%), despite the risk of infectious complications [369].
On the other hand, in animal studies, administration of PPI decreased systemic production of proinflammatory cytokines (TNF-α and IL-1β) and protected mice with endotoxic shock from death (60% survival vs. 5% of untreated mice) [370]; PPIs were proposed as promising drugs against sepsis and severe inflammatory conditions.
7 Mycobacterium tuberculosis Infection
A case–control study has shown that use of ASDs increases the risk of tuberculosis infection/activation (6541 cases): OR 1.63 with PPIs and OR 1.51 with HR2As [371]. However, in a sample of near 62,000 patients, long-term PPI therapy was not associated with increased risk of acquiring gastrointestinal tuberculosis [372].
8 Furunculosis
A case of recurrent furunculosis associated with repeated courses of omeprazole therapy was reported [373]. Six cycles of furunculosis occurred mainly on the patient’s neck; each episode developed within 1–2 weeks of starting omeprazole, continued to be present through the duration of therapy, and resolving within 1–2 weeks of discontinuation of the drug.
9 Fungal Infections
Although Candida spp. commonly colonise the gastrointestinal tract in healthy humans [374, 375], high levels of their presence are associated with several severe diseases [374, 376–381]. Significant Candida overgrowth has been detected in duodenal aspirates [382] and gastric juice of peptic ulcer patients treated with H2RAs [383, 384] or omeprazole [384]. The fungal isolation rate was higher in older patients and in subjects with post-treatment gastric pH of ≥4 [384]. Candidiasis of the small intestine in association with ASDs has also been reported [385]. In healthy volunteers and gastric ulcer patients, 5 weeks of omeprazole therapy resulted in a significant bacterial and Candida albicans overgrowth in the gastric juice and jejunum fluid [386]. Surgical interventions producing hypoacidity such as vagotomy [387] or partial gastrectomy [388] are associated with massive C. albicans overgrowth. Other researchers, however, reported similar positive candidal culture rates in the stomach in patients receiving PPI (17.3%) or H2RA (11.5%) and not treated with ASDs (12.5%), although PPI use was associated with higher intra-gastric bacterial infection rates (66.7, 46.2 and 28.8%, respectively) [379]. In gastric ulcer patients treated with H2Ras, C. albicans infection did not affect the healing rate and healing time [389], while in rats, persistent colonisation with C. albicans induced with ranitidine delayed ulcer healing [390].
Systemic candidiasis, a common opportunistic infection, has been observed in immunocompromised patients treated with cimetidine [391]. Candida esophagitis has been linked to ASDs. There are case-reports of esophageal candidiasis associated with H2RSs [392, 393] and omeprazole therapy [393–397] even if patients lacked other risk factors. A recent retrospective analysis of 55,314 Koreans who underwent a screening esophagogastroduodenoscopy revealed that ASD use is an independent risk factor (OR 5.11) for Candida esophagitis in addition to malignancy (OR 18.68), use of steroids (OR 6.74) and diabetes mellitus (OR 2.67). It is thought that the physiological reflux of gastric acid into the esophagus may inhibit esophageal colonization by Candida spp. [394]. In contrast, a large (80,219 patients) Japanese endoscopic-based study did not find a significant association of PPI use with Candida esophagitis [398]. A case-controlled study of adult surgical ICU patients showed that the proportion of intra-abdominal Candida infection among patients receiving ASDs and non-ASD users was similar (30.3 vs. 32.1%), although higher in chronic PPI users and those with prior abdominal surgery [399]. Empiric antifungal therapy in patients with complicated intra-abdominal infection with a history of prior use of ASDs was not recommended. Of practical importance is the antagonism of PPIs and antifungal agent fluconazole [400]. Avoidance of coadministration of PPIs and antifungal posaconazole has been shown to be effective in neutropenic haematological patients [401]. On the other hand, as both voriconazole, a broad-spectrum antifungal drug used in severe fungal infections, and PPIs undergo hepatic cytochrome P450-dependent metabolism mainly through isoenzymes CYP2C19, CYP3A4, CYP2C9, their concurrent administration significantly increases total voriconazole exposure and may be used to achieve higher plasma concentrations [402, 403].
10 Parasitic Protozoan Infections
No published reports on ASD-related parasitic protozoan diseases were found. In contrast, there are data that ASDs may be beneficial, exerting antimalarial and anti-leishmanial activities (two most significant of the protozoan parasites that infect man). Astemizole, an antihistamine, has been shown to inhibit chloroquine-sensitive and multidrug-resistant Plasmodium falciparum parasites, and the drug was effective in two mouse models of malaria [404]. Studies in vitro demonstrated antimalarial activity of omeprazole against trophozoites, schizonts and ring forms [405]. Combination of omeprazole with quinine had a synergistic antimalarial effect, combination of omeprazole with artemisinin drugs had an additive effect, but when omeprazole was used with chloroquine an antagonistic effect was observed [406].
In regard to cutaneous leishmaniasis, it has been reported that omeprazole and rifampicin are a highly effective combination [392, 407]. Oral cimetidine or omeprazole [408] with low dose of systemic meglumine antimoniate are recommended in high-risk patients with heart, kidney, and/or liver disease.
In the context of enormous health, social, and economic impact of human parasitic protozoa diseases (about a million deaths annually), particularly in tropical and subtropical regions of the world, lack of vaccines and limited therapeutic strategies, ASDs appear as attractive adjuvants to antiprotozoal therapy.
Interestingly, cimetidine has been found to enhance the protective effect of a schistosome vaccine [409] and omeprazole synergistically increased the efficiency of praziquantel against schistosomiasis [410], indicating advances that may arise from use of ASDs.
11 Viral and Prion Infections
The data on pathophysiology and clinical significance of ASDs in human viral infections are scarce. Because many viruses are sensitive to the low pH in the gastric juice [291, 411, 412], patients with hypochlorhydria may be predisposed to viral and prion infections [156]. It has been shown that influenza viruses infect and persist in gastric mucosa in patients receiving ASDs [413]. Community-acquired respiratory infections, which are mainly viral in origin, are more common in ASD users (OR 2.34) [326]. A recent review and meta-analysis found that pooled prevalence of influenza viruses in stool was 20.6%, but the occurrence of gastrointestinal symptoms among patients with influenza was inconsistent [414]. In mice, given brain homogenates contaminated with scrapie via gastric intubation, lower doses of infectious material induced disease more often when gastric acidity was reduced by adding ranitidine to the drinking water [415]. In a similar model, omeprazole-induced gastric hypoacidity more than doubled the rate of brain infection [416]. These experiments indicate the important protective role of gastric juice against orally acquired prion diseases (transmissible spongiform encephalopathies), subacute neurodegenerative disorders with an inexorably lethal outcome.
12 Colonisation by Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus (VRE)
Advanced age, healthcare contact, invasive medical interventions, chronic illnesses and antibiotic use are well-known risk factors for nosocomial antimicrobial-resistant infections, including MRSA and VRE [417–423], which have become pandemic in recent decades causing a major public health problem, serious morbidity and mortality globally [424, 425]. A high prevalence of colonisation with MRSA, VRE, penicillin-resistant pneumococci, extended spectrum beta-lactamase-producing and fluoroquinolone-resistant Gram-negative organisms (K. pneumonia, E. coli) has been well documented in the elderly, especially among residents of long-term care facilities [426–437]. Although production of gastric acid has been recognised among factors contributing to colonisation resistance [438], the possible effect of the widely used ASDs on the dissemination of nosocomial pathogens has only been addressed in a few studies. Suppression of gastric acid with an H2RA and administration of antibiotics resulted in colonisation of MRSA in the small intestine in immunosuppressed mice [439]. Similarly, in clindamycin-treated mice, use of a PPI tripled the rate of colonisation of the large intestine by ingested vancomycin-resistant Enterococcus spp. and K. pneumoniae [440]. An increased risk of MRSA colonisation associated with ASDs use (adjusted OR 7.12) was reported in ambulatory inflammatory bowel disease patients [441]. Use of antacids was identified as an independent risk factor for acquisition of VRE in a burn ICU (OR 24.2) [442], as well as in a cohort of hospitalised patients (OR 2.9) [443]. VRE colonisation was independently associated with PPI use in liver transplant candidates (OR 2.7) [444]. Use of H2RAs was found to be a predictor of bacteraemia and colonisation with extended-spectrum beta-lactamase-producing Enterobacteriaceae (area under receiver operator characteristic curve 0.8) [445]. Taking together, these observations suggest that gastric acid suppression by ASDs may act as a factor contributing to colonisation/infection with MRSA, VRE and other antibiotic-resistant bacilli. It should be noted that subjects who are colonised with these organisms, even when at low risk of developing clinical disease (asymptomatic carriers), may act as reservoirs for spreading the infectious agents to other persons, especially in RCFs.
13 Proposed Pathogenic Mechanisms of ASD-Associated Infections
The available data, although incomplete and conflicting, suggest that use of ASDs, especially PPIs, may predispose susceptible individuals to infections, in particular the elderly and frail persons with multiple comorbidities, who are more likely to be prescribed these medications as well as antibiotics. The underlying biological mechanisms involved in ASD-associated infections are complex and still not fully understood. The promising and plausible biological mechanisms related to pleiotropic effects of ASDs include: (1) inhibition of gastric secretion and gastric emptying [446] and suppression of gastrointestinal motility [213, 274, 447, 448], (2) immune dysfunction (reduction of the immune-mediated resilience to infections), direct effects on the activity of neutrophils, monocytes, endothelial, and epithelial cells [449, 450], (3) metabolic disorders such as vitamin (B12, C) and mineral deficiencies (iron, magnesium and calcium) [5, 451–453], (4) increased mucosal permeability [216, 454–456]—all factors resulting in (5) disruption of the natural gut microbial flora and predisposing to infectious diseases. These ASD-associated conditions may exert their effects separately but usually in concert; and in each infection type, despite differences in biology, predisposing and initiating events, the above-mentioned pathophysiological factors are linked and overlap.
The elderly, understandably, are potentially at higher risk of ASD-associated infections due to age-related decreased gastric acidity, often esophageal and gastro-intestinal motility disorders, impaired phagocytosis, decreased antibody production and compromised immune system—immunosenescence [457–461]. In addition, impaired drug metabolism (e.g. in advanced cirrhosis), especially of PPIs (except rabeprazole), may result in higher exposure to PPIs [33, 257].
13.1 Inhibition of Gastric Secretion
High gastric acidity, in combination with pepsin, lipase and mucus is a fundamental, though non-specific, natural physiological barrier against a variety of ingested bacterial and parasitic pathogens [307, 462–469]. Not surprisingly, alteration in this defence system—both acquired and iatrogenic gastric hypochlorhydria/achlorhydria—increases susceptibility to and severity of enteric infections [147, 156, 191, 195, 294, 307, 470–472] caused by bacteria such as Salmonella, Cholera, E. coli, Campylobacter and Yersinia species [156, 473], parasites and viruses; the strongest evidence is on non-typhoid salmonellosis and cholera [156, 307, 463, 474]. In mice with hypochlorhydria caused by mutation in a gastric H+/K+-ATPase (proton pump) gene significantly greater numbers of Salmonella, Yersinia, and Citrobacter cells and Clostridium spores survived, resulting in reduced median infectious doses [475]. In general, the risk of clinical infection is higher in PPIs users compared to persons receiving H2RAs because of greater gastric acid suppression with PPIs. On the other hand, some bacteria and fungi, known to inhabit the human body, contain proton pumps which belong to the family of P-type ATPases which includes the human gastric H+/K+-ATPase [476–478]. Therefore, potentially PPIs may directly target the proton pumps of these bacteria and fungi, for example, in H. pylori [479, 480], some Streptococcus spp. [481] and fungi [477, 482].
It should also be recognised that bacteria, viruses and parasites have multifaceted repertoires of strategies to evade host’s defence systems including the ability to reduce gastric secretion of acid [156, 463] and mucus production [468] as well as affect immune responses.
Loss of this major non-specific defensive mechanism—the increase in gastric pH by ASDs—allows pharyngeal commensals and ingested environmental organisms (most of which, except H. pylori, are not adapted to low pH) to survive, proliferate and colonise in the stomach, to pass into the duodenum and further along the gastrointestinal tract causing gastrointestinal dysbiosis. The normal gastrointestinal flora maintains the histological structure of the gut mucosa and is an extremely important host defence mechanism, highly effective in protecting against colonisation by potentially pathogenic invaders. The qualitative and quantitative alterations in the gut microbiota may result in a number of intestinal and extra-intestinal infections.
13.2 Effects of ASDs Unrelated to the Inhibition of Gastric Acid Secretion
The ability of a microorganism to cause infectious disease is a function of both its intrinsic virulence and the host’s defence barriers, which include immunological competence. The ASDs in addition to the inhibition of gastric acid secretion directly and indirectly influence multiple functions related to the immunological defence status [450]. PPIs reduce different neutrophil functions [483–486], including phagocytosis and acidification of phagolysosomes [487], adhesion of neutrophils to endothelial cells [488, 489], exhibit anti-oxidant properties [449, 490–497], suppress the expression of tumour necrosis factor-alpha, interleukins (IL-6, IL-8, IL-1β), intracellular and vascular adhesion molecules [488, 498–501], inhibit the nitric oxide synthase [501, 502] and lysosomal enzymes [503], dose-dependently decrease production of pro-inflammatory/profibrotic cytokines by epithelial and endothelial cells [450, 499, 504, 505], decrease natural killer cell cytotoxic activity in a dose-dependent manner [506], impair neutrophil migration from vessels to inflammatory sites by preventing the activation of heparanase [486], mitigate neutrophil adherence to endothelial cell [500], affect neutrophil chemotaxis and phagocytosis of micro-organisms [216, 483, 487, 507]. These mechanisms, although some of them remain hypothetic, might compromise immunity, contribute to bacterial colonisation and a variety of inflammatory and infectious disorders. Noteworthy, the rise of intralysosomal pH by PPIs is considered the major mode of the direct antileishmanial in vivo [392, 508] and antimalarial in vitro activities [405] and in the inhibition of the rhinovirus infection in cultured human epithelial cells [504]. PPIs might also be potentially beneficial in inflammatory diseases, in which the role of acid and pepsin is minimal (e.g. eosinophilic esophagitis, idiopathic pulmonary fibrosis) [450], as well as for antineoplastic therapeutic regimens [500, 509–512].
Immunomodulation effects of H2RAs have also been documented [332, 513]. Histamine plays an important role in the regulation of neutrophil-dominant inflammatory reactions mediating an oxidative burst, one of the most important defence mechanisms for the elimination of invading microorganisms [514–517]. H2 receptors (as well as H1 and H4 receptors) are expressed in neutrophils and other immune cells [518–521]. The results from experimental studies on the effects of H2RAs on neutrophils, monocytes and other cells are controversial [515–518, 522–526]. Clinical observations indicate that H2RAs may improve postoperative immunosuppression [523, 527], modulate IL-6 signal transduction and reduce CRP levels [528]. A potential beneficial impact of H2RAs in the treatment of multiple myeloma [522], gastrointestinal and breast cancers has also been reported [529, 530].
Altogether, simultaneous suppression of gastric secretion and modulation of multiple factors involved in the pathogenesis of infection and cell homeostasis by ASDs might affect the complex host-infective agent relationship and explain the increased incidence of infectious diseases among some ASD users, but beneficial effects in other patients (e.g. postoperative, with cancer, some parasitic infections, idiopathic pulmonary fibrosis, etc.). This suggests that the resulting effect should be considered in each patient individually taking into account the appropriateness of ASD use, underlying comorbid conditions, their severity and other medications prescribed. There is a need for a paradigm shift in the ASD use from disease-oriented to an individual patient-oriented. The risk of ASD-associated infections is usually the result of a complex interaction between multiple mechanisms, including ASD exposure-induced dysbiosis and altered immunity, as well as the patient’s underlying immunological status, which may be affected by the different conditions and diseases (age, CVDs, DM, COPD, oropharyngeal dysphagia, CLD, CKD, cancer, polypharmacy, immunosuppressive drugs, indwelling devices, etc.) (Fig. 1).
13.3 ASDs and CDI
With regard to the association of ASDs with CDI, it should be noted that C. difficile vegetative forms (not spores which are acid-resistant [531]) are normally killed by gastric acid but survive when the pH >5, and the stool samples of infected individuals contain 10-fold more vegetative cells than spores [532]. Bile salts, as has been shown in the Syrian hamster, stimulate the transition of C. difficile spores to vegetative cells in the duodenum and small intestine [533]. Therefore, reduced gastric acidity together with presence of bile salts in gastric contents [e.g. in gastrointestinal reflux disease (GERD)] may affect C. difficile spore germination, facilitate the survival of the vegetative forms [534] and allow them to move down causing gut dysbiosis [199, 535] and predisposing to CDI [536, 537]. ASD-associated bacterial overgrowth increases levels of unconjugated bile acids [294] and might further facilitate CDI. However, the relationship between bile acids and CDI is complex [538, 539], no change in any of ten dominant human primary and secondary bile acids has been observed in healthy volunteers receiving high doses of PPIs (40 mg omeprazole, twice daily) [129].
Recent studies indicate that ASDs, especially PPIs, may increase risk of CDI by (1) altering composition of the gut microbiota [537] (towards a less healthy one), in particular the taxa involved in colonisation resistance to C. difficile (increased Enterococcaceae and Streptococceae, decreased Clostridiales) and taxa associated with gastrointestinal bacterial overgrowth (increased Micrococcaceae and Staphylococcaceae) [129, 130, 535, 537, 538, 540, 541], (2) affecting C. difficile toxin gene expression [542], (3) increasing the pathways corresponding to genes for bacterial invasion of epithelial cells and for renin-angiotensin system [129], and decreasing the expression of genes responsible for colonocyte integrity [543], and (4) directly acting on specific bacterial taxa (e.g. some Streptococceae species), which contain proton pumps belonging to the same enzyme family as the human H+/K+-ATPase [478, 481]. Taking together, the available clinical and animal [70] data indicate that ASDs may directly and indirectly affect the gut microbiome and, therefore, increase the risk of CDI. Importantly, on the population level, PPIs more than antibiotics or other used drugs are associated with profound gut microbial alterations [535].
13.4 ASDs and Pneumonia
With regard to bacterial pneumonia in patients treated with ASDs, the possible explanations and the consequence of events include (1) rise in gastric pH, promoting the proliferation of bacteria, the upper gastrointestinal tract and tracheobronchial colonisation [544–546], (2) pulmonary micro-aspiration and bacterial exchanges between the gastric and lung fluids [547], bacterial passage into the lungs and overgrowth/colonisation [198, 200, 223, 330] together (3) with impaired immune and neutrophil functions [449, 488]. In a large healthy twin cohort, PPI users demonstrated a significant increase in Streptococcaceae family [537], whereas an increased risk of community-acquired pneumonia has been reported specifically for Streptococcus-derived pneumonia [548]. These observations support the view that in PPI users the gut is likely to become a reservoir for potential pathogens [537]. Furthermore, it has been shown that depletion of the gut microbiota reduces immune-mediated resilience to pneumococcal pneumonia in mice [549]. The postulated biological mechanisms for higher pneumonia risk in ASD users, however, do not fully explain why in some studies the correlation was weaker with the longer medication use [326, 329, 330]. Although protopathic bias (when a pharmaceutical agent is prescribed for an early manifestation of the disease that has not yet been diagnosed) could not be excluded, it is possible that susceptibility to pneumonia individuals (comorbid conditions, advanced age, poor health and immunocompromised status) might develop the disease sooner after starting ASDs [294, 334, 550, 551]. In H2RAs users, this phenomenon may also be related, at least partially, to tolerance to H2RAs (usually within the first 2 weeks) which causes decline in acid suppression.
13.5 ASDs and SBP
In immunodeficient liver cirrhosis patients, the development of ASD-associated infections, including SBP, might be related to the effects of these medications on the balance between immune defences and intestinal flora. The decreased granulocyte and monocyte oxidative burst by PPIs [552], ASD-induced dysbiosis [209] with increased intestinal permeability [456] and impaired liver drug metabolism have been suggested as important pathophysiological factors for explanation of the risk of SBP in ASD users.
14 Practical Implications
The reviewed scientific literature demonstrates that ASDs, which, undoubtedly, are of great value for treatment and prophylaxis of acid-related diseases, may be associated with an increased risk of infections, especially in the elderly. Although extensive associations between ASDs and a number of infections have been reported, it should be emphasised that most of the information was derived from observational retrospective cohort or case–control studies, and systematic reviews evaluating these studies revealed bias in selection, misclassification, interpretation and residual confounding; the observed associations may be confounded by multiple coexisting conditions and do not prove causality. It should also be recognised that prospective randomised controlled studies which are often considered the “gold standard” would not only be difficult to perform (e.g. recruitment of frail elderly patients, costs, etc.) and ethically questionable, but may not provide absolute certainty [553]. Despite the limitations of the available data, current lack of conclusive evidence of causality, the existing reports on possible adverse effects of ASD therapy should not be ignored, but adequately interpreted and properly applied into everyday clinical practice.
Accumulating evidence suggests that adverse effects of ASDs (mainly of PPIs) in addition to infections may include poorer cardiovascular outcomes [554], an increased risk of CKD [555], fractures, especially of the hip [123, 556–573], vitamin and mineral deficiencies [574–576], altered mental status and delirium [577, 578], development of enterochromaffin-like cell hyperplasia [579], risk of gastric neuroendocrine tumours [580], and fundic gland polyps [581]. The complexity of therapeutic ASD use is further increased by drug-drug interactions (pharmacokinetic and pharmacodynamic), which, not surprisingly, are particularly common in the elderly due to polytherapy [582]. Clinically relevant interactions were reported for PPIs with clopidogrel [583–586], dabigatran [587], bisphosphonates [559, 568], metformin [588, 589], methotrexate [590–593], antidepressants and antipsychotics [38], fluconazole [400, 594], immunosuppressants (e.g. mycophenolate) [595–597], magnesium oxide [598], different anti-cancer and antiviral medications [599, 600]. In addition, all ASDs by increasing gastric pH can affect the bioavailability of several other drugs (e.g. iron salts, ampicillin, ketoconazole). H2RAs decrease absorption of magnesium oxide [598] and dasatinib [601, 602].
Although the reports on adverse drug-drug interactions with PPIs are conflicting and when evaluated in systemic reviews such events were found to be rare and the increased risk, for the most part, mild-modest [600], a careful individualised judgement in patients taking above-mentioned medications before prescribing ASDs is needed. For example, use of ASDs was shown to be associated with an increased risk of hip fracture only among persons with at least one risk factor for osteoporosis [603]; H. pylori positivity was found to be a significant independent risk factor for osteoporosis but its eradication was not [604].
When choosing an ASD, in general a relatively safe medication [605, 606], to manage gastric acid-related disorders the potential for possible spectrum of adverse events, drug-drug, drug-nutrient interactions and agent-specific side effects should be considered. For each individual patient, the balance of risk and benefits, agent of choice, the possible dose, and duration of use, requires careful attention.
Unnecessary or inappropriate use of ASDs, especially of PPIs, has been consistently documented in the adult population (ranged from 34.2 to 63%) [22, 29, 294, 607–614], including hospitalised patients (26.8–73.9%) [23, 25, 26, 440, 609, 615–622] and after discharge (>50–80.2%) [616, 618–620, 623–625] as well as among nursing home residents (24–93%) [626–630]. Long-term use of ASDs, which are now available over-the-counter in many countries, may represent a prescribing cascade [630] with minimal therapeutic benefits and excess costs [606, 618, 621, 623]; unfortunately, the inappropriate use of ASDs is increasing [631], especially among patients of a lower socio-demographic status [611, 631].
On the other hand, there are reports that ASDs are underused. For example, only 31.7% of patients with Barrett’s esophagus or GERD were prescribed either PPI or H2RA [632], adequate gastroprotection was not provided to more than 50% of short-term users of NSAIDs who were at an increased risk for upper gastrointestinal complications [633], and only 3.5% of low-dose aspirin users received PPIs, H2RAs or mucoprotective drugs [634]. Because the world population is ageing and age is an important risk factor for CVDs, arthritis and chronic pain, as well as for antiplatelet- and NSAID-associated ulcers and bleeding [635–638], in the coming years the prophylactic ASD use is likely to increase significantly. A recent meta-analysis demonstrated that the combination of selective COX-2 inhibitors with PPIs provides the best gastrointestinal protection, followed by selective COX-2 inhibitors, whereas co-administration of H2RAs with nonselective NSAIDs did not significantly reduce the risk of clinical gastrointestinal events [639]. PPI therapy is needed in 10 high-risk and 268 moderate-risk patients to prevent one NSAID-related ulcer [640].
The data presented above raise serious challenges and the following steps may be helpful in clinical practice when considering ASD treatment: (1) evaluate for evidence-based indications for ASD therapy, (2) weigh the risks for adverse effects of ASDs in the individual patient (primum non nocere, do not harm), (3) assess potential drug-drug interactions, (4) choose an adequate drug, dose (minimal effective) and duration (consider discontinuation if indications are not certain) tailored to the specific constellation of a patient’s conditions and preferences, (5) consider interventions that may prevent/reduce infectious and other adverse effects associated with ASD use, and (6) monitor the patient carefully after therapy starts and decide when it could be ceased (Fig. 2). While basic sanitation, hand-washing and monitoring of antibiotics use remain central to preventing and limiting nosocomial infections, appropriate use of ASDs, especially in elderly, chronically ill and immunosuppressed patients, is also important.
ASD-associated infections (and other adverse effects) are not a class effect. Differences of clinical relevance exist between PPIs and H2RAs as well as in the pharmacokinetic profiles of individual PPIs and H2RAs. These include (1) absorption of H2RAs is not affected by food, while meal-related dosing is necessary with PPIs especially when treating GERD; (2) tolerance to H2RAs, though of minor clinical significance, may develop after 2–7 days of therapy [641, 642], but tolerance does not occur with PPIs [643]; (3) in patients with renal impairment, the doses of H2RAs, but not of PPIs, should be reduced [644–648]; (4) although PPIs in general are more effective than H2RAs in preventing upper GI bleeding, the increased risk of CDI, pneumonia and other infections as well as fracture is lower in patients taking H2RAs compared with patients taking PPIs; (5) the risk of drug interactions mediated by cytochrome P450 enzymes should be considered for both omeprazole and cimetidine (because of their high affinity for CYP2C19 concomitant use of these medications with clopidogrel affects the biotransformation of clopidogrel by competitive inhibition of CYP2C19 [649–652]); in contrast, other PPIs (pantoprazole, lansoprazole, rabeprazole, esomeprazole and dexlansoprazole [600]) and H2RAs (famotidine, nizatidine or ranitidine, rabeprazole [653, 654]) have lower potential for drug-drug interactions; however this suggestion has not been fully confirmed in a recent meta-analysis [655]. Omeprazole when used concomitantly with protease inhibitors can cause different adverse effects [503] because of its potent pH alteration and inhibition of p-glycoprotein pathway [590]. These potential benefits and harms of PPIs and H2RAs should be considered before initiating ASDs to manage gastric acid-related disorders, especially if treatment includes polypharmacy, which for vulnerable geriatric patients can be unavoidable [656, 657].
As PPIs which are associated with a variety of adverse events do not reduce the number of reflux events and do not provide long-term cure for GERD, use of H2RAs and prokinetics and non-medical interventions should also be considered [658].
Although ASD prophylaxis against stress ulceration in critically ill patients has been part of routine clinical practice for several decades, the data on its benefits are controversial [353, 354, 359, 363, 364, 659–663]. It was concluded that the quantity and quality of evidence supporting the use of ASDs in ICU is low [664, 665]; PPIs might reduce the rate of gastrointestinal bleeding, but increase rates of nosocomial infections (especially pneumonia and CDI), myocardial ischemia [666] and mortality (e.g. patients with liver cirrhosis) [667]. The recommended alternatives to PPI prophylaxis are H2RAs [667] and sucralfate [332, 353, 358, 667], an agent which does not alter gastric pH and exerts its topical effect by binding to proteins of the ulcer site [332, 353, 358, 667]. In contrast, in three other meta-analyses, PPIs were superior to H2RAs in preventing gastrointestinal bleeding without significantly increasing the risk of pneumonia or mortality [363, 364].
Finally, strategies for reducing potential ASD-associated infections in addition to avoiding inappropriate prescribing, implementation of standardised guidelines, antibiotic stewardship programmes and sound infection control practices, should, as adjuvant therapy, consider: (1) use of probiotics (live microorganisms with beneficial physiologic or therapeutic properties) or prebiotics (non-digestible dietary components that beneficially affects the host by stimulating the growth and/or activity of beneficial bacteria in the colon) and (2) correction of the vitamin D status. Implications of such potentially effective interventions have been, unfortunately, largely overlooked.
Currently, probiotics are recommended and used (with varying success) to protect against infections [668, 669], particularly for reduction of antibiotic-induced primary CDI [66, 670–681], travel-related diarrhoea associated with antibiotic use [682], especially in the elderly [683], and as adjuvant therapy for H. pylori eradication therapy [8, 684, 685], as well as for acute upper respiratory tract infections [686, 687], ventilator-associated pneumonia in critically ill patients [688, 689], pneumonia caused by K. pneumonia (in mice) [690], urogenital infections [691], postoperative infections [692] and oral candidiasis [693] protection. Because ASD-related alterations in composition and function of the microbiota are associated with the development of infections, use of pro- and prebiotics may provide a simple preventive measure in ASD users. It is well documented that the gut microbiome plays a significant role in the regulation of host metabolism and immunity [694–710], and a wide variety of systemic diseases and conditions are associated with gut dysbiosis. Increased intake of yogurt with a sufficient number of viable probiotic bacteria (mainly Lactobacillus and Bifidobacterium spp.) positively modulates gut microbiota, prevents dysbiosis, improves immune status [705, 711–713], the barrier function of the gut [697, 714] and possess antagonistic activity against C. difficile, S. aureus, Salmonella spp., E. coli, P. aeruginosa, Enterobacter, L. monocytogenes, C. perfringens and other bacterial agents [705, 715–721]. Also reduces gastrointestinal carriage of VRE [722, 723], displays antiviral, detoxifying, cholesterol-lowering, anti-diabetic and antioxidant properties [705]. Therefore, it is likely that probiotic use, a diet rich in yogurt and fibre may have significant potential health and nutritional benefits, including a protective effect on decreasing the incidence of ASD-associated infections, especially in the elderly [724, 725]. Such an approach can be considered a promising add-on therapy to counteract the effects of ASDs on gut dysbiosis. However, because of existing gaps in the understanding the human microbiota and the multiple mechanisms by which probiotics modulate various physiological functions, challenges and concerns persist regarding appropriate treatment regimens (specific probiotic strain(-s), most effective combinations, optimum dosing, use of nutrients), and even safety (mainly the potential of opportunistic infection in immunocompromised patients) [705, 714, 726–728] and genetic stability.
Recent research demonstrated the critical role of vitamin D in human innate and adaptive immunity [729–731]. Vitamin D insufficiency, which is highly prevalent (40–60% in the healthy general adult population), may lead to dysregulation of immune responses and increases susceptibility for infections and mortality in different settings [732–737]. Vitamin D deficiency is also reported to be associated with increased risk [738] and greater severity of CDI in some [739–741] but not all [742] studies. Animal studies found that dietary-induced vitamin D deficiency increases susceptibility to Citrobacter rodentium-induced colitis and exacerbates intestinal inflammatory response impairing mucosal defence [743]. Although results of several trials assessing the effects of vitamin D supplementation on infections were mixed [732, 736, 744–746], the currently available balance of evidence supports such intervention as a promising one for prevention the risk of infectious diseases, including ASD-related diseases. Potential benefits of correction of vitamin D insufficiency and maintaining vitamin D levels in the normal range also include reduced risk of many common bone, immune, cardiovascular, renal, liver, metabolic, malignant, and mental disorders, as well as mortality; these have been shown in numerous observational studies and meta-analyses, but adequate randomised trials are still lacking.
In view of current evidence and the underlying biological plausibility adding probiotics (e.g. yoghurt) and correcting vitamin D status may have beneficial consequences. However, given the limited and conflicting reports, further well-designed studies are needed to determine the effects of both probiotics and vitamin D supplementation as adjunctive therapies in infection prevention.
We hope that this review will help clinicians cope with information overload, enable them to individualise decisions regarding the use of ASDs, selection of a specific drug, and clearly discuss the balance between benefits and potential harms with the patient before starting long-term treatment.
15 Conclusions
Development and use of ASDs (H2RAs and PPIs), one of the most commonly prescribed classes of medications, has been revolutionary. Their therapeutic and prophylactic benefits are well recognised and the absolute risk of the complications including ASD-associated infectious diseases is relatively low. Accumulating data, however, indicate the complexity of ASD effects involving important defence systems, non-immunological and immunological, resulting in dysbiosis and increased risk for enteric, including CDI, and other infections, particularly in the elderly. Despite the limitations of the existing data, the importance of individualised therapy and caution in long-term ASD use considering the balance of benefits and potential harms, factors that may predispose to and actions that may prevent/attenuate adverse effects is evident. A six-step practical algorithm for ASD therapy based on the best available evidence is presented.
References
Fisher L, Fisher A, Pavli P, Davis M. Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention. Aliment Pharmacol Ther. 2007;25(3):297–308.
Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 2007;11(51):iii–iv, 1–164.
Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528–34.
Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med. 2013;41(3):693–705.
Heidelbaugh JJ. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf. 2013;4(3):125–33.
Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013;27(3):443–54.
Medlock S, Eslami S, Askari M, Taherzadeh Z, Opondo D, de Rooij SE, et al. Co-prescription of gastroprotective agents and their efficacy in elderly patients taking nonsteroidal anti-inflammatory drugs: a systematic review of observational studies. Clin Gastroenterol Hepatol. 2013;11(10):1259–69 e10.
Safavi M, Sabourian R, Foroumadi A. Treatment of Helicobacter pylori infection: current and future insights. World J Clin Cases. 2016;4(1):5–19.
Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006;2:CD003840.
Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88(4):1547–65.
Katz PO, Scheiman JM, Barkun AN. Review article: acid-related disease–what are the unmet clinical needs? Aliment Pharmacol Ther. 2006;23(Suppl 2):9–22.
Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.
Scarpignato C, Gatta L, Zullo A, Blandizzi C, Group S-A-F, Italian Society of Pharmacology tIAoHG, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16(19):2323–30.
Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015;41(11):1162–74.
Labenz J, Willmer C. Efficacy and safety of OTC omeprazole. MMW Fortschr Med. 2012;17(154 Suppl 4):110–4.
Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359(16):1700–7.
Pea F. Antimicrobial treatment of bacterial infections in frail elderly patients: the difficult balance between efficacy, safety and tolerability. Curr Opin Pharmacol. 2015;24:18–22.
Leibovici L, Paul M. Ethical dilemmas in antibiotic treatment: focus on the elderly. Clin Microbiol Infect. 2015;21(1):27–9.
Marcum ZA, Hanlon JT, Strotmeyer ES, Newman AB, Shorr RI, Simonsick EM, et al. Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time. J Am Geriatr Soc. 2014;62(10):1923–7.
Opondo D, Visscher S, Eslami S, Verheij RA, Korevaar JC, Abu-Hanna A. Quality of co-prescribing NSAID and gastroprotective medications for elders in the Netherlands and its association with the electronic medical record. PLoS One. 2015;10(6):e0129515.
Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009;104(Suppl 2):S27–32.
Durand C, Willett KC, Desilets AR. Proton pump inhibitor use in hospitalized patients: is overutilization becoming a problem? Clin Med Insights Gastroenterol. 2012;5:65–76.
Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012;72(4):437–45.
Kelly OB, Dillane C, Patchett SE, Harewood GC, Murray FE. The inappropriate prescription of oral proton pump inhibitors in the hospital setting: a prospective cross-sectional study. Dig Dis Sci. 2015;60(8):2280–6.
Delcher A, Hily S, Boureau AS, Chapelet G, Berrut G, de Decker L. Multimorbidities and overprescription of proton pump inhibitors in older patients. PLoS One. 2015;10(11):e0141779.
Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66(6):582–91.
Buckley MS, Park AS, Anderson CS, Barletta JF, Bikin DS, Gerkin RD, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015;128(8):905–13.
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.
Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Baillieres Clin Gastroenterol. 1993;7(1):23–54.
Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, et al. Pharmacological aspects of acid secretion. Dig Dis Sci. 1995;40(2 Suppl):3S–23S.
Jain KS, Shah AK, Bariwal J, Shelke SM, Kale AP, Jagtap JR, et al. Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorg Med Chem. 2007;15(3):1181–205.
Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54.
Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004;32(8):821–7.
Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs—focus on rabeprazole. J Gastroenterol Hepatol. 2005;20(Suppl):S22–8.
Fock KM, Ang TL, Bee LC, Lee EJ. Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes? Clin Pharmacokinet. 2008;47(1):1–6.
Kuo CH, Wang SS, Hsu WH, Kuo FC, Weng BC, Li CJ, et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265–72.
Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39(11):2020–33.
Reynolds JC. The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol. 1990;12(Suppl 2):S54–63.
Tuskey A, Peura D. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S6.
Aymard JP, Aymard B, Netter P, Bannwarth B, Trechot P, Streiff F. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988;3(6):430–48.
Fisher AA, Le Couteur DG. Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf. 2001;24(1):39–57.
Powell JR, Donn KH. The pharmacokinetic basis for H2-antagonist drug interactions: concepts and implications. J Clin Gastroenterol. 1983;5(Suppl 1):95–113.
Penston J, Wormsley KG. Adverse reactions and interactions with H2-receptor antagonists. Med Toxicol. 1986;1(3):192–216.
Hansten PD. Overview of the safety profile of the H2-receptor antagonists. DICP. 1990;24(11 Suppl):S38–41.
Chen Y, Liu BC, Glass K, Kirk MD. High incidence of hospitalisation due to infectious gastroenteritis in older people associated with poor self-rated health. BMJ Open. 2015;5(12):e010161.
Leufkens H, Claessens A, Heerdink E, van Eijk J, Lamers CB. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997;11(5):887–97.
Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol. 2000;50(4):366–72.
Claessens AA, Heerdink ER, van Eijk JT, Lamers CB, Leufkens HG. Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute? Pharmacoepidemiol Drug Saf. 2002;11(8):703–8.
Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 2003;26(2):121–32.
McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998;16(5):292–307.
Jansen A, Stark K, Kunkel J, Schreier E, Ignatius R, Liesenfeld O, et al. Aetiology of community-acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC Infect Dis. 2008;8:143.
McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78.
Chui KK, Jagai JS, Griffiths JK, Naumova EN. Hospitalization of the elderly in the United States for nonspecific gastrointestinal diseases: a search for etiological clues. Am J Public Health. 2011;101(11):2082–6.
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.
Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis. 2012;55(7):982–9.
Viswanathan VK, Mallozzi MJ, Vedantam G. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes. 2010;1(4):234–42.
Pilotto A, Franceschi M, Vitale D, Zaninelli A, Di Mario F, Seripa D, et al. The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol. 2008;103(11):2816–23.
Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(6):651–68.
Magill SS, Edwards JR, Fridkin SK, Emerging Infections Program Healthcare-Associated I, Antimicrobial Use Prevalence Survey T. Survey of health care-associated infections. N Engl J Med. 2014;370(26):2542–3.
Dubberke E. Strategies for prevention of Clostridium difficile infection. J Hosp Med. 2012;7(Suppl 3):S14–7.
Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–98 (quiz 99).
Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182–9.
Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59–73.
Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–34.
Goldstein EJ, Johnson S, Maziade PJ, McFarland LV, Trick W, Dresser L, et al. Pathway to prevention of nosocomial Clostridium difficile infection. Clin Infect Dis. 2015;15(60 Suppl 2):S148–58.
Gao T, He B, Pan Y, Deng Q, Sun H, Liu X, et al. Association of Clostridium difficile infection in hospital mortality: a systematic review and meta-analysis. Am J Infect Control. 2015;43(12):1316–20.
Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol. 2011;8(1):17–26.
Halabi WJ, Nguyen VQ, Carmichael JC, Pigazzi A, Stamos MJ, Mills S. Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg. 2013;217(5):802–12.
Schubert AM, Sinani H, Schloss PD. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio. 2015;6(4):e00974.
Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–16.
Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin N Am. 2015;29(1):37–50.
Hunter JC, Mu Y, Dumyati GK, Farley MM, Winston LG, Johnston HL, et al. Burden of nursing home-onset Clostridium difficile infection in the United States: estimates of incidence and patient outcomes. Open Forum Infect Dis. 2016;3(1):ofv196.
Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013;173(14):1359–67.
Claesson MJ, Cusack S, O’Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA. 2011;15(108 Suppl 1):4586–91.
Depestel DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26(5):464–75.
Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med. 2014;30(1):79–93.
Rodriguez C, Korsak N, Taminiau B, Avesani V, Van Broeck J, Delmee M, et al. Clostridium difficile infection in elderly nursing home residents. Anaerobe. 2014;30:184–7.
Pawar D, Tsay R, Nelson DS, Elumalai MK, Lessa FC, Clifford McDonald L, et al. Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. Infect Control Hosp Epidemiol. 2012;33(11):1107–12.
Laffan AM, Bellantoni MF, Greenough WB 3rd, Zenilman JM. Burden of Clostridium difficile-associated diarrhea in a long-term care facility. J Am Geriatr Soc. 2006;54(7):1068–73.
Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review. J Am Geriatr Soc. 2010;58(8):1556–64.
Zilberberg MD, Nathanson BH, Sadigov S, Higgins TL, Kollef MH, Shorr AF. Epidemiology and outcomes of Clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. Chest. 2009;136(3):752–8.
Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53(12):1173–8.
Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1–8.
Mizusawa M, Doron S, Gorbach S. Clostridium difficile diarrhea in the elderly: current issues and management options. Drugs Aging. 2015;32(8):639–47.
Drekonja DM, Amundson WH, Decarolis DD, Kuskowski MA, Lederle FA, Johnson JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124(11):1081 e1–.
Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70(2):142–7.
Furuya-Kanamori L, Stone JC, Clark J, McKenzie SJ, Yakob L, Paterson DL, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36(2):132–41.
Lin HJ, Hung YP, Liu HC, Lee JC, Lee CI, Wu YH, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect. 2015;48(2):183–9.
Johanesen PA, Mackin KE, Hutton ML, Awad MM, Larcombe S, Amy JM, et al. Disruption of the gut microbiome: Clostridium difficile infection and the threat of antibiotic resistance. Genes (Basel). 2015;6(4):1347–60.
Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;15(46 Suppl 1):S12–8.
Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33(Suppl 1):S33–6.
Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539–48.
Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6(2):105–8.
Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci. 2007;37(3):241–7.
Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;64(22):2359–63.
Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(9):2308–13.
Cunningham R, Dial S. Is over-use of proton pump inhibitors fuelling the current epidemic of Clostridium difficile-associated diarrhoea? J Hosp Infect. 2008;70(1):1–6.
Pant C, Madonia P, Minocha A. Does PPI therapy predispose to Clostridium difficile infection? Nat Rev Gastroenterol Hepatol. 2009;6(9):555–7.
Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.
Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011;34(11–12):1269–81.
Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf. 2011;20(10):1035–42.
Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.
Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.
Pohl JF. Clostridium difficile infection and proton pump inhibitors. Curr Opin Pediatr. 2012;24(5):627–31.
Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(3):225–33.
Tleyjeh IM, Abdulhak AB, Riaz M, Garbati MA, Al-Tannir M, Alasmari FA, et al. The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. PLoS One. 2013;8(3):e56498.
Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, AlGhamdi M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7(12):e50836.
Vesteinsdottir I, Gudlaugsdottir S, Einarsdottir R, Kalaitzakis E, Sigurdardottir O, Bjornsson ES. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case–control study. Eur J Clin Microbiol Infect Dis. 2012;31(10):2601–10.
Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, et al. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(11):1466–71.
Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085–90.
Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11):1794–801.
Biswal S. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea. Biomed J. 2014;37(4):178–83.
McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;175(5):784–91.
Ro Y, Eun CS, Kim HS, Kim JY, Byun YJ, Yoo KS, et al. Risk of Clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically ill patients. Gut Liver. 2016;10(4):581–6.
Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54(3):243–5.
Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294(23):2989–95.
Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther. 2006;24(4):613–9.
Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.
Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.
Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56 (quiz 57).
Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013;6(4):443–51.
Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone. 2011;48(4):768–76.
Brown KE, Knoderer CA, Nichols KR, Crumby AS. Acid-suppressing agents and risk for Clostridium difficile infection in pediatric patients. Clin Pediatr (Phila). 2015;54(11):1102–6.
Buendgens L, Bruensing J, Matthes M, Duckers H, Luedde T, Trautwein C, et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J Crit Care. 2014;29(4):696 e11–5.
Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014;7:63–72.
Davies EA, O’Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol. 2015;80(4):796–807.
Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. BMJ Open Gastroenterol. 2015;2(1):e000028.
Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5 e9.
Bajaj JS, Cox IJ, Betrapally NS, Heuman DM, Schubert ML, Ratneswaran M, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol. 2014;307(10):G951–7.
Yoo DH, Kim IS, Van Le TK, Jung IH, Yoo HH, Kim DH. Gut microbiota-mediated drug interactions between lovastatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508–13.
Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000;93(3):175–81.
Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60.
Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.
Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis. 2006;43(10):1272–6.
Naggie S, Miller BA, Zuzak KB, Pence BW, Mayo AJ, Nicholson BP, et al. A case–control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors. Am J Med. 2011;124(3):276 e1–7.
Novack L, Kogan S, Gimpelevich L, Howell M, Borer A, Kelly CP, et al. Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias. PLoS One. 2014;9(10):e110790.
Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21(22):6817–9.
Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23(11):653–9.
Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–42.
Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not increase risk for Clostridium difficile infection in the intensive care unit. Am J Gastroenterol. 2016;111(11):1641–8.
de la Coba Ortiz C, Arguelles Arias F, de Argila Martin, de Prados C, Judez Gutierrez J, Linares Rodriguez A, Ortega Alonso A, et al. Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espanola de Patologia Digestiva. Rev Esp Enferm Dig. 2016;108(4):207–24.
Ruddell WS, Losowsky MS. Severe diarrehoea due to small intestinal colonisation during cimetidine treatment. Br Med J. 1980;281(6235):273.
Wingate DL. Acid reduction and recurrent enteritis. Lancet. 1990;335(8683):222.
Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312(7028):414–5.
Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5(12):1418–23.
Wu HH, Chen YT, Shih CJ, Lee YT, Kuo SC, Chen TL. Association between recent use of proton pump inhibitors and nontyphoid salmonellosis: a nested case–control study. Clin Infect Dis. 2014;59(11):1554–8.
Bouwknegt M, van Pelt W, Kubbinga ME, Weda M, Havelaar AH. Potential association between the recent increase in campylobacteriosis incidence in the Netherlands and proton-pump inhibitor use—an ecological study. Euro Surveillance. 2014;19(32).
Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–4.
Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, Hoebee B, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136(9):1225–34.
Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. 1994;308(6922):176.
Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134(3):617–26.
Bowen A, Newman A, Estivariz C, Gilbertson N, Archer J, Srinivasan A, et al. Role of acid-suppressing medications during a sustained outbreak of Salmonella enteritidis infection in a long-term care facility. Infect Control Hosp Epidemiol. 2007;28(10):1202–5.
Giannella RA, Broitman SA, Zamcheck N. Salmonella enteritis. I. Role of reduced gastric secretion in pathogenesis. Am J Dig Dis. 1971;16(11):1000–6.
Gray JA, Trueman AM. Severe salmonella gastroenteritis associated with hypochlorhydria. Scott Med J. 1971;16(5):255–8.
Martinsen TC, Bergh K, Waldum HL. Gastric juice: a barrier against infectious diseases. Basic Clin Pharmacol Toxicol. 2005;96(2):94–102.
Kunz LJ, Waddell WR. Association of Salmonella enteritis with operations on the stomach. N Engl J Med. 1956;255(12):555–9.
Close AS, Smith MB, Koch ML, Ellison EH. An analysis of ten cases of Salmonella infection on a general surgical service. Arch Surg. 1960;80:972–6.
Sokol EM. Salmonella derby infections after gastrointestinal surgery. J Mt Sinai Hosp N Y. 1965;32:36–41.
Buchin PJ, Andriole VT, Spiro HM. Salmonella infections and hypochlorhydria. J Clin Gastroenterol. 1980;2(2):133–8.
Collins FM. Salmonellosis in orally infected specific pathogen-free C57B1 mice. Infect Immun. 1972;5(2):191–8.
Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J Infect Dis. 1988;157(3):472–9.
Brophy S, Jones KH, Rahman MA, Zhou SM, John A, Atkinson MD, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013;108(7):1094–100.
Fujita T. Risk factors of community-acquired enteric infection. Am J Gastroenterol. 2014;109(1):137–8.
Ramaswamy V, Cresence VM, Rejitha JS, Lekshmi MU, Dharsana KS, Prasad SP, et al. Listeria—review of epidemiology and pathogenesis. J Microbiol Immunol Infect. 2007;40(1):4–13.
Swaminathan B, Gerner-Smidt P. The epidemiology of human listeriosis. Microbes Infect. 2007;9(10):1236–43.
White SJ, McClung DM, Wilson JG, Roberts BN, Donaldson JR. Influence of pH on bile sensitivity amongst various strains of Listeria monocytogenes under aerobic and anaerobic conditions. J Med Microbiol. 2015;64(11):1287–96.
Hernandez-Milian A, Payeras-Cifre A. What is new in listeriosis? Biomed Res Int. 2014;2014:358051.
Gillespie IA, McLauchlin J, Little CL, Penman C, Mook P, Grant K, et al. Disease presentation in relation to infection foci for non-pregnancy-associated human listeriosis in England and Wales, 2001 to 2007. J Clin Microbiol. 2009;47(10):3301–7.
Kasper S, Huhulescu S, Auer B, Heller I, Karner F, Wurzner R, et al. Epidemiology of listeriosis in Austria. Wien Klin Wochenschr. 2009;121(3–4):113–9.
Gerner-Smidt P, Ethelberg S, Schiellerup P, Christensen JJ, Engberg J, Fussing V, et al. Invasive listeriosis in Denmark 1994–2003: a review of 299 cases with special emphasis on risk factors for mortality. Clin Microbiol Infect. 2005;11(8):618–24.
Preussel K, Milde-Busch A, Schmich P, Wetzstein M, Stark K, Werber D. Risk factors for sporadic non-pregnancy associated listeriosis in Germany-immunocompromised patients and frequently consumed ready-to-eat products. PLoS One. 2015;10(11):e0142986.
Huang YT, Ko WC, Chan YJ, Lu JJ, Tsai HY, Liao CH, et al. Disease burden of invasive listeriosis and molecular characterization of clinical isolates in Taiwan, 2000–2013. PLoS One. 2015;10(11):e0141241.
Ho JL, Shands KN, Friedland G, Eckind P, Fraser DW. An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals. Arch Intern Med. 1986;146(3):520–4.
Kader SA, Mansour AM, Mohran Z, el-Taoil A, Abdalla KF. A study on the relation between proton pump inhibitor and gastric giardiasis. J Egypt Soc Parasitol. 1998;28(1):149–57.
Cobb CA, Curtis GD, Bansi DS, Slade E, Mehal W, Mitchell RG, et al. Increased prevalence of Listeria monocytogenes in the faeces of patients receiving long-term H2-antagonists. Eur J Gastroenterol Hepatol. 1996;8(11):1071–4.
Schlech WF 3rd, Chase DP, Badley A. A model of food-borne Listeria monocytogenes infection in the Sprague–Dawley rat using gastric inoculation: development and effect of gastric acidity on infective dose. Int J Food Microbiol. 1993;18(1):15–24.
Ferreira A, Sue D, O’Byrne CP, Boor KJ. Role of Listeria monocytogenes sigma(B) in survival of lethal acidic conditions and in the acquired acid tolerance response. Appl Environ Microbiol. 2003;69(5):2692–8.
Sleator RD, Watson D, Hill C, Gahan CG. The interaction between Listeria monocytogenes and the host gastrointestinal tract. Microbiology. 2009;155(Pt 8):2463–75.
Gahan CG, Hill C. Listeria monocytogenes: survival and adaptation in the gastrointestinal tract. Front Cell Infect Microbiol. 2014;4:9.
Smith JL, Liu Y, Paoli GC. How does Listeria monocytogenes combat acid conditions? Can J Microbiol. 2013;59(3):141–52.
Cristiano P, Paradisi F. Can cimetidine facilitate infections by oral route. Lancet. 1982;2(8288):45.
Steffen R. Antacids—a risk factor in travellers brucellosis? Scand J Infect Dis. 1977;9(4):311–2.
Antacids and brucellosis. Br Med J. 1978;1(6115):739–40.
Osband ME, Cohen EB, Miller BR, Shen YJ, Cohen L, Flescher L, et al. Biochemical analysis of specific histamine HI and H2 receptors on lymphocytes. Blood. 1981;58(1):87–90.
Thornes RD. Cimetidine and brucellosis. Lancet. 1982;2(8291):217.
Fakir M, Saison C, Wong T, Matta B, Hardin JM. Septicemia due to Yersinia enterocolitica in a hemodialyzed, iron-depleted patient receiving omeprazole and oral iron supplementation. Am J Kidney Dis. 1992;19(3):282–4.
Peterson WL, Mackowiak PA, Barnett CC, Marling-Cason M, Haley ML. The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences. J Infect Dis. 1989;159(5):979–83.
Evans CA, Gilman RH, Rabbani GH, Salazar G, Ali A. Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg. 1997;91(6):681–5.
DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis. 1972;125(1):5–11.
Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. 1980;1(8170):672–4.
Muscroft TJ, Keighley MR. Cimetidine, gastric pH, and nitrosation. Lancet. 1981;1(8227):1002.
Reed PI, Haines K, Smith PL, Walters CL, House FR. Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet. 1982;2(8288):39.
Stockbrugger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines, and bacterial overgrowth during cimetidine treatment. Gut. 1982;23(12):1048–54.
Stockbruegger RW. Bacterial overgrowth as a consequence of reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:7–16.
Sharma BK, Santana IA, Wood EC, Walt RP, Pereira M, Noone P, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed). 1984;289(6447):717–9.
Verdu E, Viani F, Armstrong D, Fraser R, Siegrist HH, Pignatelli B, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35(4):455–60.
Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50–4.
Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15(3):511–21.
Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.
Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8(6):574–81.
Shindo K, Machida M, Koide K, Fukumura M, Yamazaki R. Deconjugation ability of bacteria isolated from the jejunal fluid of patients with progressive systemic sclerosis and its gastric pH. Hepatogastroenterology. 1998;45(23):1643–50.
Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44(5):598–602.
Mowat C, Williams C, Gillen D, Hossack M, Gilmour D, Carswell A, et al. Omeprazole, Helicobacter pylori status, and alterations in the intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology. 2000;119(2):339–47.
Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Double gastric infection with Helicobacter pylori and non-Helicobacter pylori bacteria during acid-suppressive therapy: increase of pro-inflammatory cytokines and development of atrophic gastritis. Aliment Pharmacol Ther. 2001;15(8):1163–75.
Milton-Thompson GJ, Lightfoot NF, Ahmet Z, Hunt RH, Barnard J, Bavin PM, et al. Intragastric acidity, bacteria, nitrite, and N-nitroso compounds before, during, and after cimetidine treatment. Lancet. 1982;1(8281):1091–5.
Viani F, Siegrist HH, Pignatelli B, Cederberg C, Idstrom JP, Verdu EF, et al. The effect of intra-gastric acidity and flora on the concentration of N-nitroso compounds in the stomach. Eur J Gastroenterol Hepatol. 2000;12(2):165–73.
Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104.
Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–7.
Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35(1):23–6.
Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106(3):615–23.
Gough A, Andrews D, Bacon PA, Emery P. Evidence of omeprazole-induced small bowel bacterial overgrowth in patients with scleroderma. Br J Rheumatol. 1995;34(10):976–7.
Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61.
Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y). 2007;3(2):112–22.
Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8(6):504–8.
van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, de Rooij FW, Siersema PD, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest. 2012;42(7):760–7.
Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Aliment Pharmacol Ther. 2013;37(11):1103–11.
Freedberg DE, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. Clin Lab Med. 2014;34(4):771–85.
Franco DL, Disbrow MB, Kahn A, Koepke LM, Harris LA, Harrison ME, et al. Duodenal aspirates for small intestine bacterial overgrowth: yield, PPIs, and outcomes after treatment at a tertiary academic medical center. Gastroenterol Res Pract. 2015;2015:971582.
Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008;103(12):2972–6.
Altman KW, Chhaya V, Hammer ND, Pavlova S, Vesper BJ, Tao L, et al. Effect of proton pump inhibitor pantoprazole on growth and morphology of oral Lactobacillus strains. Laryngoscope. 2008;118(4):599–604.
Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.
Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54–9.
Iivonen MK, Ahola TO, Matikainen MJ. Bacterial overgrowth, intestinal transit, and nutrition after total gastrectomy. Comparison of a jejunal pouch with Roux-en-Y reconstruction in a prospective random study. Scand J Gastroenterol. 1998;33(1):63–70.
Paik CN, Choi MG, Lim CH, Park JM, Chung WC, Lee KM, et al. The role of small intestinal bacterial overgrowth in postgastrectomy patients. Neurogastroenterol Motil. 2011;23(5):e191–6.
Schiller LR. Evaluation of small bowel bacterial overgrowth. Curr Gastroenterol Rep. 2007;9(5):373–7.
Corazza GR, Menozzi MG, Strocchi A, Rasciti L, Vaira D, Lecchini R, et al. The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology. 1990;98(2):302–9.
Ratuapli SK, Ellington TG, O’Neill MT, Umar SB, Harris LA, Foxx-Orenstein AE, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol. 2012;107(5):730–5.
Schatz RA, Zhang Q, Lodhia N, Shuster J, Toskes PP, Moshiree B. Predisposing factors for positive d-xylose breath test for evaluation of small intestinal bacterial overgrowth: a retrospective study of 932 patients. World J Gastroenterol. 2015;21(15):4574–82.
Fujiwara Y, Watanabe T, Muraki M, Yamagami H, Tanigawa T, Shiba M, et al. Association between chronic use of proton pump inhibitors and small-intestinal bacterial overgrowth assessed using lactulose hydrogen breath tests. Hepatogastroenterology. 2015;62(138):268–72.
Brechmann T, Sperlbaum A, Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: results of a retrospective cohort study. World J Gastroenterol. 2017;23(5):842–52.
Cares K, Al-Ansari N, Macha S, Zoubi N, Zaghloul H, Thomas R, et al. Risk of small intestinal bacterial overgrowth with chronic use of proton pump inhibitors in children. Eur J Gastroenterol Hepatol. 2017;29(4):396–9.
Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract. 2013;28(3):289–99.
Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, et al. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro. J Immunol. 1994;152(6):3189–98.
Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis—a longitudinal study. PLoS One. 2013;8(4):e62885.
Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.
Strid H, Simren M, Stotzer PO, Ringstrom G, Abrahamsson H, Bjornsson ES. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. Digestion. 2003;67(3):129–37.
Patil AD. Link between hypothyroidism and small intestinal bacterial overgrowth. Indian J Endocrinol Metab. 2014;18(3):307–9.
McLean MH, Dieguez D Jr, Miller LM, Young HA. Does the microbiota play a role in the pathogenesis of autoimmune diseases? Gut. 2015;64(2):332–41.
Vanner S. The small intestinal bacterial overgrowth. Irritable bowel syndrome hypothesis: implications for treatment. Gut. 2008;57(9):1315–21.
Carrara M, Desideri S, Azzurro M, Bulighin GM, Di Piramo D, Lomonaco L, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2008;12(3):197–202.
Andalib I, Shah H, Bal BS, Shope TR, Finelli FC, Koch TR. Breath hydrogen as a biomarker for glucose malabsorption after Roux-en-Y gastric bypass surgery. Dis Markers. 2015;2015:102760.
Sung HJ, Paik CN, Chung WC, Lee KM, Yang JM, Choi MG. Small intestinal bacterial overgrowth diagnosed by glucose hydrogen breath test in post-cholecystectomy patients. J Neurogastroenterol Motil. 2015;21(4):545–51.
Capurso G, Signoretti M, Archibugi L, Stigliano S, Delle Fave G. Systematic review and meta-analysis: small intestinal bacterial overgrowth in chronic pancreatitis. United Eur Gastroenterol J. 2016;4(5):697–705.
Therrien A, Bouchard S, Sidani S, Bouin M. Prevalence of small intestinal bacterial overgrowth among chronic pancreatitis patients: a case–control study. Can J Gastroenterol Hepatol. 2016;2016:7424831.
Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: the clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol. 2015;7(3):304–14.
Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–21.
Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis. 2008;28(1):26–42.
Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol. 2012;56(Suppl 1):S1–12.
Luo JC, Leu HB, Hou MC, Huang CC, Lin HC, Lee FY, et al. Cirrhotic patients at increased risk of peptic ulcer bleeding: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2012;36(6):542–50.
Kuo MT, Yang SC, Lu LS, Hsu CN, Kuo YH, Kuo CH, et al. Predicting risk factors for rebleeding, infections, mortality following peptic ulcer bleeding in patients with cirrhosis and the impact of antibiotics prophylaxis at different clinical stages of the disease. BMC Gastroenterol. 2015;15:61.
Venkatesh PG, Parasa S, Njei B, Sanaka MR, Navaneethan U. Increased mortality with peptic ulcer bleeding in patients with both compensated and decompensated cirrhosis. Gastrointest Endosc. 2014;79(4):605–14 e3.
Lodato F, Azzaroli F, Di Girolamo M, Feletti V, Cecinato P, Lisotti A, et al. Proton pump inhibitors in cirrhosis: tradition or evidence based practice? World J Gastroenterol. 2008;14(19):2980–5.
Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol. 2009;104(5):1130–4.
Siple JF, Morey JM, Gutman TE, Weinberg KL, Collins PD. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Ann Pharmacother. 2012;46(10):1413–8.
Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10(4):422–7.
Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol. 2014;28(6):330–4.
Min YW, Lim KS, Min BH, Gwak GY, Paik YH, Choi MS, et al. Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study. Aliment Pharmacol Ther. 2014;40(6):695–704.
Chang SS, Lai CC, Lee MT, Lee YC, Tsai YW, Hsu WT, et al. Risk of spontaneous bacterial peritonitis associated with gastric acid suppression. Medicine (Baltimore). 2015;94(22):e944.
Sargenti K, Prytz H, Strand A, Nilsson E, Kalaitzakis E. Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome. Liver Int. 2015;35(2):391–400.
Merli M, Lucidi C, Di Gregorio V, Giannelli V, Giusto M, Ceccarelli G, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–9.
O’Leary JG, Reddy KR, Wong F, Kamath PS, Patton HM, Biggins SW, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015;13(4):753–9 e1–2.
Choi EJ, Lee HJ, Kim KO, Lee SH, Eun JR, Jang BI, et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol. 2011;46(5):616–20.
Dultz G, Piiper A, Zeuzem S, Kronenberger B, Waidmann O. Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther. 2015;41(5):459–66.
Dam G, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology. 2016;64(4):1265–72.
Yu T, Tang Y, Jiang L, Zheng Y, Xiong W, Lin L. Proton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta-analysis. Dig Liver Dis. 2016;48(4):353–9.
Xu HB, Wang HD, Li CH, Ye S, Dong MS, Xia QJ, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015;14(3):7490–501.
Trikudanathan G, Israel J, Cappa J, O’Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients—a systematic review and meta-analysis. Int J Clin Pract. 2011;65(6):674–8.
Deshpande A, Pasupuleti V, Thota P, Pant C, Mapara S, Hassan S, et al. Acid-suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. J Gastroenterol Hepatol. 2013;28(2):235–42.
Huang KW, Kuan YC, Luo JC, Lin CL, Liang JA, Kao CH. Impact of long-term gastric acid suppression on spontaneous bacterial peritonitis in patients with advanced decompensated liver cirrhosis. Eur J Intern Med. 2016;32:91–5.
Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, et al. Proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in population study. Gastroenterology. 2017;152(1):134–41.
Miozzo SA, Tovo CV, John JA, de Mattos AA. Proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhosis: an undesirable association? J Hepatol. 2015;63(2):529–30.
Terg R, Casciato P, Garbe C, Cartier M, Stieben T, Mendizabal M, et al. Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study. J Hepatol. 2015;62(5):1056–60.
de Vos M, De Vroey B, Garcia BG, Roy C, Kidd F, Henrion J, et al. Role of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascites. Liver Int. 2013;33(9):1316–23.
Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Summereder C, et al. Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. PLoS One. 2014;9(11):e110503.
Lo EA, Wilby KJ, Ensom MH. Use of proton pump inhibitors in the management of gastroesophageal varices: a systematic review. Ann Pharmacother. 2015;49(2):207–19.
Picardi A, Vespasiani-Gentilucci U. Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther. 2016;7(1):1–4.
Garcia-Saenz-de-Sicilia M, Sanchez-Avila F, Chavez-Tapia NC, Lopez-Arce G, Garcia-Osogobio S, Ruiz-Cordero R, et al. PPIs are not associated with a lower incidence of portal-hypertension-related bleeding in cirrhosis. World J Gastroenterol. 2010;16(46):5869–73.
Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut. 2015;64(11):1680–704.
Meli M, Raffa MP, Malta R, Morreale I, Aprea L, D’Alessandro N. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients. Int J Clin Pharm. 2015;37(6):1152–61.
Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, La De, Cuesta FS, Spanish Collaborative Study Group On Therapeutic Management In Liver D. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435–40.
Chavez-Tapia NC, Tellez-Avila FI, Garcia-Leiva J, Valdovinos MA. Use and overuse of proton pump inhibitors in cirrhotic patients. Med Sci Monit. 2008;14(9):CR468–72.
Perez-Fontan M, Machado Lopes D, Garcia Enriquez A, Lopez-Calvino B, Lopez-Muniz A, Garcia Falcon T, et al. Inhibition of gastric acid secretion by H2 receptor antagonists associates a definite risk of enteric peritonitis and infectious mortality in patients treated with peritoneal dialysis. PLoS One. 2016;11(2):e0148806.
Wang YP, Liu CJ, Chen TJ, Lin YT, Fung CP. Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study. Aliment Pharmacol Ther. 2015;41(11):1175–81.
Schneider J, Weidner W, Hapfelmeier A, Wantia N, Feihl S, Schmid RM, et al. The use of proton pump inhibitors and the spectrum and number of biliary pathogens in patients with acute cholangitis. Aliment Pharmacol Ther. 2014;39(10):1194–203.
Yardley JH, Bayless TM. Giardiasis. Gastroenterology. 1967;52(2):301–4.
Buret AG. Mechanisms of epithelial dysfunction in giardiasis. Gut. 2007;56(3):316–7.
Di Genova BM, Tonelli RR. Infection strategies of intestinal parasite pathogens and host cell responses. Front Microbiol. 2016;7:256.
Lane S, Lloyd D. Current trends in research into the waterborne parasite Giardia. Crit Rev Microbiol. 2002;28(2):123–47.
Haas J, Bucken EW. On the pathogenicity of the lamblia infections. Dtsch Med Wochenschr. 1967;92(41):1869–71.
Cook GC. Infective gastroenteritis and its relationship to reduced gastric acidity. Scand J Gastroenterol Suppl. 1985;111:17–23.
Doglioni C, De Boni M, Cielo R, Laurino L, Pelosio P, Braidotti P, et al. Gastric giardiasis. J Clin Pathol. 1992;45(11):964–7.
Misra V, Misra SP, Dwivedi M, Singh PA. Giardia lamblia trophozoites in gastric biopsies. Indian J Pathol Microbiol. 2006;49(4):519–23.
Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56(4):931–50.
Reynaert H, Fernandes E, Bourgain C, Smekens L, Devis G. Proton-pump inhibition and gastric giardiasis: a causal or casual association? J Gastroenterol. 1995;30(6):775–8.
Mukherjee S. Asymptomatic giardiasis—an association with proton pump inhibitors? Am J Gastroenterol. 2000;95(12):3666–7.
Francois M, Levy-Bohbot N, Caron J, Durlach V. Chronic use of proton-pump inhibitors associated with giardiasis: a rare cause of hypomagnesemic hypoparathyroidism? Ann Endocrinol (Paris). 2008;69(5):446–8.
Khatami SS, Mukunda B, Ravakhah K. Coinfection with Giardia lamblia and Clostridium difficile after use of ranitidine. Am J Med Sci. 2004;327(2):91–3.
Slonim JM, Ireton HJ, Smallwood RA. Giardiasis following gastric surgery. Aust N Z J Med. 1976;6(5):479–80.
Reyes-Vivas H, de la mora-de la Mora I, Castillo-Villanueva A, Yepez-Mulia L, Hernandez-Alcantara G, Figueroa-Salazar R, et al. Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia. Antimicrob Agents Chemother. 2014;58(12):7072–82.
Grove DI. Strongyloidiasis: a conundrum for gastroenterologists. Gut. 1994;35(4):437–40.
Johnston FH, Morris PS, Speare R, McCarthy J, Currie B, Ewald D, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health. 2005;13(4):247–54.
Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, et al. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8(8):e3018.
Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol. 2005;39(3):203–11.
Rivasi F, Pampiglione S, Boldorini R, Cardinale L. Histopathology of gastric and duodenal Strongyloides stercoralis locations in fifteen immunocompromised subjects. Arch Pathol Lab Med. 2006;130(12):1792–8.
Buonfrate D, Requena-Mendez A, Angheben A, Munoz J, Gobbi F, Van Den Ende J, et al. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis. 2013;13:78.
Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78(2):271–6.
Ainley CC, Clarke DG, Timothy AR, Thompson RP. Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy. Gut. 1986;27(3):337–8.
Shafaghi A, Askari K, Hajizadeh H, Mansour-Ghanaei F. Gastric strongyloidiasis as multiple small gastric nodules. Am J Case Rep. 2012;13:7–10.
Cadranel JF, Eugene C. Another example of Strongyloides stercoralis infection associated with cimetidine in an immunosuppressed patient. Gut. 1986;27(10):1229.
Wurtz R, Mirot M, Fronda G, Peters C, Kocka F. Short report: gastric infection by Strongyloides stercoralis. Am J Trop Med Hyg. 1994;51(3):339–40.
Owen DG. Attempts at oral infection of rats and mice with trophozoites of Entamoeba histolytica. Trans R Soc Trop Med Hyg. 1984;78(2):160–4.
Makioka A, Kumagai M, Kobayashi S, Takeuchi T. Effect of artificial gastrointestinal fluids on the excystation and metacystic development of Entamoeba invadens. Parasitol Res. 2006;98(5):443–6.
Lambrecht E, Bare J, Chavatte N, Bert W, Sabbe K, Houf K. Protozoan cysts act as a survival niche and protective shelter for foodborne pathogenic bacteria. Appl Environ Microbiol. 2015;81(16):5604–12.
Lambrecht E, Bare J, Van Damme I, Bert W, Sabbe K, Houf K. Behavior of Yersinia enterocolitica in the presence of the bacterivorous Acanthamoeba castellanii. Appl Environ Microbiol. 2013;79(20):6407–13.
Axelsson-Olsson D, Svensson L, Olofsson J, Salomon P, Waldenstrom J, Ellstrom P, et al. Increase in acid tolerance of Campylobacter jejuni through coincubation with amoebae. Appl Environ Microbiol. 2010;76(13):4194–200.
Gutierrez F, Masia M. Improving outcomes of elderly patients with community-acquired pneumonia. Drugs Aging. 2008;25(7):585–610.
Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–27.
Dhawan N, Pandya N, Khalili M, Bautista M, Duggal A, Bahl J, et al. Predictors of mortality for nursing home-acquired pneumonia: a systematic review. Biomed Res Int. 2015;2015:285983.
Feldman C, Anderson R. Community-acquired pneumonia: pathogenesis of acute cardiac events and potential adjunctive therapies. Chest. 2015;148(2):523–32.
Teramoto S, Yoshida K, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig. 2015;53(5):178–84.
Ebihara S, Sekiya H, Miyagi M, Ebihara T, Okazaki T. Dysphagia, dystussia, and aspiration pneumonia in elderly people. J Thorac Dis. 2016;8(3):632–9.
Wirth R, Dziewas R, Beck AM, Clave P, Hamdy S, Heppner HJ, et al. Oropharyngeal dysphagia in older persons—from pathophysiology to adequate intervention: a review and summary of an international expert meeting. Clin Interv Aging. 2016;11:189–208.
Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346.
Komiya K, Ishii H, Kadota J. Healthcare-associated pneumonia and aspiration pneumonia. Aging Dis. 2015;6(1):27–37.
Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther. 2003;18(8):847–51.
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310–9.
Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.
Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med. 2007;167(9):950–5.
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.
Eom CS, Park SM, Myung SK, Yun JM, Ahn JS. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257–67.
O’Keefe GE, Gentilello LM, Maier RV. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients. Ann Surg. 1998;227(1):120–5.
Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.
Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.
Lee SW, Lin CH, Lien HC, Lee TY, Yeh HZ, Chang CS. Proton pump inhibitors did not increase risk of pneumonia in patients with chronic obstructive pulmonary disease. J Clin Med Res. 2015;7(11):880–3.
Chen CH, Lin HC, Lin HL, Lin YT, Chou JM, Hsu SP, et al. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease. J Microbiol Immunol Infect. 2015;48(4):390–6.
Ran L, Khatibi NH, Qin X, Zhang JH. Proton pump inhibitor prophylaxis increases the risk of nosocomial pneumonia in patients with an intracerebral hemorrhagic stroke. Acta Neurochir Suppl. 2011;111:435–9.
Ho SW, Hsieh MJ, Yang SF, Yeh YT, Wang YH, Yeh CB. Risk of stroke-associated pneumonia with acid-suppressive drugs: a population-based cohort study. Medicine (Baltimore). 2015;94(29):e1227.
Arai N, Nakamizo T, Ihara H, Koide T, Nakamura A, Tabuse M, et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. PLoS One. 2017;12(1):e0169300.
Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–8.
Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22(9):761–6.
Estborn L, Joelson S. Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials. Drug Saf. 2008;31(7):627–36.
Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42(5):607–13.
Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR. Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med. 2010;123(1):47–53.
Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case–control study. Pharmacoepidemiol Drug Saf. 2010;19(8):792–802.
Momosaki R, Yasunaga H, Matsui H, Fushimi K, Abo M. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis. 2016;25(5):1035–40.
Yamanaka Y, Mammoto T, Kita T, Kishi Y. A study of 13 patients with gastric tube in place after esophageal resection: use of omeprazole to decrease gastric acidity and volume. J Clin Anesth. 2001;13(5):370–3.
Kiljander TO. The role of proton pump inhibitors in the management of gastroesophageal reflux disease-related asthma and chronic cough. Am J Med. 2003;18(115 Suppl 3A):65S–71S.
Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, et al. Randomised clinical trial: high-dose acid suppression for chronic cough—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):225–34.
Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assuncao AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol. 2014;18(2):184–91.
Xu X, Lv H, Yu L, Chen Q, Liang S, Qiu Z. A stepwise protocol for the treatment of refractory gastroesophageal reflux-induced chronic cough. J Thorac Dis. 2016;8(1):178–85.
Committee CAGCA. Community-acquired pneumonia and acid-suppressive drugs: position statement. Can J Gastroenterol. 2006;20(2):119–21, 23–5.
Cook DJ. Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis. Scand J Gastroenterol Suppl. 1995;210:48–52.
Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996;275(4):308–14.
Bardou M, Quenot JP, Barkun A. Stress-related mucosal disease in the critically ill patient. Nat Rev Gastroenterol Hepatol. 2015;12(2):98–107.
Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995;274(8):639–44.
Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987;317(22):1376–82.
Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg. 1994;220(3):353–60 (discussion 60–3).
Messori A, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ. 2000;321(7269):1103–6.
Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med. 1998;338(12):791–7.
Khorvash F, Abbasi S, Meidani M, Dehdashti F, Ataei B. The comparison between proton pump inhibitors and sucralfate in incidence of ventilator associated pneumonia in critically ill patients. Adv Biomed Res. 2014;3:52.
Barletta JF. Histamine-2-receptor antagonist administration and gastrointestinal bleeding when used for stress ulcer prophylaxis in patients with severe sepsis or septic shock. Ann Pharmacother. 2014;48(10):1276–81.
Barkun AN, Bardou M, Pham CQ, Martel M. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–20 (quiz 21).
Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, et al. Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care. 2016;20(1):120.
Viscoli C. Bloodstream infections: the peak of the iceberg. Virulence. 2016;7(3):248–51.
Yahav D, Eliakim-Raz N, Leibovici L, Paul M. Bloodstream infections in older patients. Virulence. 2016;7(3):341–52.
Del Bono V, Giacobbe DR. Bloodstream infections in internal medicine. Virulence. 2016;7(3):353–65.
Rantala A, Ovaska J. Association between medically induced achlorhydria of the stomach and a severe postoperative infection? A report of two cases. Ann Chir Gynaecol. 1994;83(3):268–70.
Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, et al. Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries. Acta Anaesthesiol Scand. 2015;59(5):576–85.
Balza E, Piccioli P, Carta S, Lavieri R, Gattorno M, Semino C, et al. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death Dis. 2016;21(7):e2304.
Hsu WH, Kuo CH, Wang SS, Lu CY, Liu CJ, Chuah SK, et al. Acid suppressive agents and risk of Mycobacterium tuberculosis: case–control study. BMC Gastroenterol. 2014;14:91.
Hong KS, Kang SJ, Choi JK, Kim JH, Seo H, Lee S, et al. Gastrointestinal tuberculosis is not associated with proton pump inhibitors: a retrospective cohort study. World J Gastroenterol. 2013;19(2):258–64.
West BC, Agastya G, Sodeman W, Callahan J. Furunculosis associated with repeated courses of omeprazole therapy. Clin Infect Dis. 1998;26(5):1234–5.
Kumamoto CA. Inflammation and gastrointestinal Candida colonization. Curr Opin Microbiol. 2011;14(4):386–91.
Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Fungal colonization of gastric mucosa and its clinical relevance. Med Sci Monit. 2001;7(5):982–8.
Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2014;20(4):O245–54.
Paiva JA, Pereira JM, Tabah A, Mikstacki A, de Carvalho FB, Koulenti D, et al. Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care. 2016;20(1):53.
Hofer U. Fungal pathogenesis: Candida’s toxic relationship with its host. Nat Rev Microbiol. 2016;14(5):268.
Zwolinska-Wcislo M, Budak A, Bogdal J, Trojanowska D, Stachura J. Effect of fungal colonization of gastric mucosa on the course of gastric ulcers healing. Med Sci Monit. 2001;7(2):266–75.
Zwolinska-Wcislo M, Brzozowski T, Budak A, Kwiecien S, Sliwowski Z, Drozdowicz D, et al. Effect of Candida colonization on human ulcerative colitis and the healing of inflammatory changes of the colon in the experimental model of colitis ulcerosa. J Physiol Pharmacol. 2009;60(1):107–18.
Standaert-Vitse A, Sendid B, Joossens M, Francois N, Vandewalle-El Khoury P, Branche J, et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol. 2009;104(7):1745–53.
Singh S, Singh N, Kochhar R, Talwar P, Mehta SK. Cimetidine therapy and duodenal candidiasis: role in healing process. Indian J Gastroenterol. 1992;11(1):21–2.
Boero M, Pera A, Andriulli A, Ponti V, Canepa G, Palmas F, et al. Candida overgrowth in gastric juice of peptic ulcer subjects on short- and long-term treatment with H2-receptor antagonists. Digestion. 1983;28(3):158–63.
Goenka MK, Kochhar R, Chakrabarti A, Kumar A, Gupta O, Talwar P, et al. Candida overgrowth after treatment of duodenal ulcer. A comparison of cimetidine, famotidine, and omeprazole. J Clin Gastroenterol. 1996;23(1):7–10.
Cipollini F, Altilia F. Candidiasis of the small intestine. Gastroenterology. 1981;81(4):825–6.
Shindo K, Machida M, Fukumura M, Koide K, Yamazaki R. Omeprazole induces altered bile acid metabolism. Gut. 1998;42(2):266–71.
Brooks JR, Smith HF, Pease FB Jr. Bacteriology of the stomach immediately following vagotomy: the growth of Candida albicans. Ann Surg. 1974;179(6):859–62.
Borg I, Heijkenskjold F, Nilehn B, Wehlin L. Massive growth of yeasts in resected stomach. Gut. 1966;7(3):244–9.
Di Febo G, Miglioli M, Calo G, Biasco G, Luzza F, Gizzi G, et al. Candida albicans infection of gastric ulcer frequency and correlation with medical treatment. Results of a multicenter study. Dig Dis Sci. 1985;30(2):178–81.
Brzozowski T, Zwolinska-Wcislo M, Konturek PC, Kwiecien S, Drozdowicz D, Konturek SJ, et al. Influence of gastric colonization with Candida albicans on ulcer healing in rats: effect of ranitidine, aspirin and probiotic therapy. Scand J Gastroenterol. 2005;40(3):286–96.
Triger DR, Goepel JR, Slater DN, Underwood JC. Systemic candidiasis complicating acute hepatic failure in patients treated with cimetidine. Lancet. 1981;2(8251):837–8.
Kochar DK, Saini G, Kochar SK, Sirohi P, Bumb RA, Mehta RD, et al. A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis. 2006;43(4):161–7.
Hendel L, Svejgaard E, Walsoe I, Kieffer M, Stenderup A. Esophageal candidosis in progressive systemic sclerosis: occurrence, significance, and treatment with fluconazole. Scand J Gastroenterol. 1988;23(10):1182–6.
Larner AJ, Lendrum R. Oesophageal candidiasis after omeprazole therapy. Gut. 1992;33(6):860–1.
Mosimann F. Esophageal candidiasis, omeprazole therapy, and organ transplantation—a word of caution. Transplantation. 1993;56(2):492–3.
Sood A, Sharma M, Jain NP, Chawla LS, Kumar R. Esophageal candidiasis following omeprazole therapy: a report of two cases. Indian J Gastroenterol. 1995;14(2):71–2.
Chocarro Martinez A, Galindo Tobal F, Ruiz-Irastorza G, Gonzalez Lopez A, Alvarez Navia F, Ochoa Sangrador C, et al. Risk factors for esophageal candidiasis. Eur J Clin Microbiol Infect Dis. 2000;19(2):96–100.
Takahashi Y, Nagata N, Shimbo T, Nishijima T, Watanabe K, Aoki T, et al. Long-term trends in esophageal candidiasis prevalence and associated risk factors with or without HIV infection: lessons from an endoscopic study of 80,219 patients. PLoS One. 2015;10(7):e0133589.
Cat TB, Charash W, Hebert J, Marden BT, Corbett SM, Ahern J, et al. Potential influence of antisecretory therapy on the development of Candida-associated intraabdominal infection. Ann Pharmacother. 2008;42(2):185–91.
Liu NN, Kohler JR. Antagonism of fluconazole and a proton pump inhibitor against Candida albicans. Antimicrob Agents Chemother. 2016;60(2):1145–7.
Cojutti P, Candoni A, Simeone E, Franceschi L, Fanin R, Pea F. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother. 2013;57(12):6081–4.
Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections. Antimicrob Agents Chemother. 2012;56(11):6001–2.
Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 2015;59(9):5548–54.
Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006;2(8):415–6.
Skinner-Adams TS, Davis TM, Manning LS, Johnston WA. The efficacy of benzimidazole drugs against Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 1997;91(5):580–4.
Skinner-Adams T, Davis TM. Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob Agents Chemother. 1999;43(5):1304–6.
Shanehsaz SM, Ishkhanian S. A comparative study between the efficacy of oral cimetidine and low-dose systemic meglumine antimoniate (MA) with a standard dose of systemic MA in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2015;54(7):834–8.
Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. J Vector Borne Dis. 2008;45(4):287–91.
Li MJ, Lei JH, Wang T, Lu SJ, Guan F, Liu WQ, et al. Cimetidine enhances the protective effect of GST DNA vaccine against Schistosoma japonicum. Exp Parasitol. 2011;128(4):427–32.
Almeida GT, Lage RC, Anderson L, Venancio TM, Nakaya HI, Miyasato PA, et al. Synergy of omeprazole and praziquantel in vitro treatment against schistosoma mansoni adult Worms. PLoS Negl Trop Dis. 2015;9(9):e0004086.
Weiss C, Clark HF. Rapid inactivation of rotaviruses by exposure to acid buffer or acidic gastric juice. J Gen Virol. 1985;66(Pt 12):2725–30.
Waldum HL, Brenna E, Sandvik AK. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf. 2002;1(1):29–38.
Hayase Y, Tobita K, Sato H. Detection of type B influenza virus genes from biopsied gastric mucosa. J Gastroenterol. 2002;37(2):101–5.
Minodier L, Charrel RN, Ceccaldi PE, van der Werf S, Blanchon T, Hanslik T, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J. 2015;12:215.
Martinsen TC, Taylor DM, Johnsen R, Waldum HL. Gastric acidity protects mice against prion infection? Scand J Gastroenterol. 2002;37(5):497–500.
Martinsen TC, Benestad SL, Moldal T, Waldum HL. Inhibitors of gastric acid secretion increase the risk of prion infection in mice. Scand J Gastroenterol. 2011;46(12):1418–22.
Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136(11):834–44.
Mody L, Maheshwari S, Galecki A, Kauffman CA, Bradley SF. Indwelling device use and antibiotic resistance in nursing homes: identifying a high-risk group. J Am Geriatr Soc. 2007;55(12):1921–6.
Tong SY, Chen LF, Fowler VG Jr. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol. 2012;34(2):185–200.
McKinnell JA, Miller LG, Eells SJ, Cui E, Huang SS. A systematic literature review and meta-analysis of factors associated with methicillin-resistant Staphylococcus aureus colonization at time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol. 2013;34(10):1077–86.
Pogorzelska-Maziarz M, Furuya EY, Larson EL. Risk factors for methicillin-resistant Staphylococcus aureus bacteraemia differ depending on the control group chosen. Epidemiol Infect. 2013;141(11):2376–83.
Forster AJ, Oake N, Roth V, Suh KN, Majewski J, Leeder C, et al. Patient-level factors associated with methicillin-resistant Staphylococcus aureus carriage at hospital admission: a systematic review. Am J Infect Control. 2013;41(3):214–20.
Tang SS, Apisarnthanarak A, Hsu LY. Mechanisms of beta-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv Drug Deliv Rev. 2014;30(78):3–13.
Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006;4(1):36–45.
van Schaik W. The human gut resistome. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140087.
Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, Kauffman CA. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994;42(10):1062–9.
Bradley SF. Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management. Drugs Aging. 1997;10(3):185–98.
Trick WE, Weinstein RA, DeMarais PL, Kuehnert MJ, Tomaska W, Nathan C, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001;49(3):270–6.
Strausbaugh LJ, Sukumar SR, Joseph CL. Infectious disease outbreaks in nursing homes: an unappreciated hazard for frail elderly persons. Clin Infect Dis. 2003;36(7):870–6.
Esposito S, Leone S, Noviello S, Lanniello F, Fiore M. Antibiotic resistance in long-term care facilities. New Microbiol. 2007;30(3):326–31.
Manzur A, Gudiol F. Methicillin-resistant Staphylococcus aureus in long-term-care facilities. Clin Microbiol Infect. 2009;15(Suppl 7):26–30.
Fisch J, Lansing B, Wang L, Symons K, Cherian K, McNamara S, et al. New acquisition of antibiotic-resistant organisms in skilled nursing facilities. J Clin Microbiol. 2012;50(5):1698–703.
Banerjee R, Johnston B, Lohse C, Porter SB, Clabots C, Johnson JR. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol. 2013;34(4):361–9.
Han JH, Maslow J, Han X, Xie SX, Tolomeo P, Santana E, et al. Risk factors for the development of gastrointestinal colonization with fluoroquinolone-resistant Escherichia coli in residents of long-term care facilities. J Infect Dis. 2014;209(3):420–5.
Fagan M, Lindbaek M, Grude N, Reiso H, Romoren M, Skaare D, et al. Antibiotic resistance patterns of bacteria causing urinary tract infections in the elderly living in nursing homes versus the elderly living at home: an observational study. BMC Geriatr. 2015;15:98.
Stine OC, Burrowes S, David S, Johnson JK, Roghmann MC. Transmission clusters of methicillin-resistant Staphylococcus Aureus in long-term care facilities based on whole-genome sequencing. Infect Control Hosp Epidemiol. 2016;37(6):685–91.
Richards CL Jr. Preventing antimicrobial-resistant bacterial infections among older adults in long-term care facilities. J Am Med Dir Assoc. 2005;6(2):144–51.
van der Waaij D. Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment. Infection. 1983;11(Suppl 2):S90–2.
Yoshida Y. Methicillin-resistant Staphylococcus aureus proliferation in the rat gut is influenced by gastric acid inhibition and the administration of antibiotics. Surg Today. 1999;29(4):327–37.
Stiefel U, Rao A, Pultz MJ, Jump RL, Aron DC, Donskey CJ. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycin-resistant Enterococcus spp. and Klebsiella pneumoniae in clindamycin-treated mice. Antimicrob Agents Chemother. 2006;50(11):3905–7.
Leung W, Malhi G, Willey BM, McGeer AJ, Borgundvaag B, Thanabalan R, et al. Prevalence and predictors of MRSA, ESBL, and VRE colonization in the ambulatory IBD population. J Crohns Colitis. 2012;6(7):743–9.
Falk PS, Winnike J, Woodmansee C, Desai M, Mayhall CG. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol. 2000;21(9):575–82.
Cetinkaya Y, Falk PS, Mayhall CG. Effect of gastrointestinal bleeding and oral medications on acquisition of vancomycin-resistant Enterococcus faecium in hospitalized patients. Clin Infect Dis. 2002;35(8):935–42.
McNeil SA, Malani PN, Chenoweth CE, Fontana RJ, Magee JC, Punch JD, et al. Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis. 2006;42(2):195–203.
Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42(7):925–34.
Sanaka M, Yamamoto T, Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci. 2010;55(9):2431–40.
Lichtenberger LM, Bhattarai D, Phan TM, Dial EJ, Uray K. Suppression of contractile activity in the small intestine by indomethacin and omeprazole. Am J Physiol Gastrointest Liver Physiol. 2015;308(9):G785–93.
Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42(2):243–50.
Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22.
Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54(11):2312–7.
Henry EB, Carswell A, Wirz A, Fyffe V, McColl KE. Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther. 2005;22(6):539–45.
McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol. 2009;104(Suppl 2):S5–9.
Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448–57.
Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008;28(11–12):1317–25.
Farrell C, Morgan M, Tully O, Wolov K, Kearney K, Ngo B, et al. Transepithelial leak in Barrett’s esophagus patients: the role of proton pump inhibitors. World J Gastroenterol. 2012;18(22):2793–7.
Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol. 2015;7(17):2058–68.
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.
Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, et al. Immunosenescence and immunogenetics of human longevity. Neuroimmunomodulation. 2008;15(4–6):224–40.
Fulop T, Dupuis G, Witkowski JM, Larbi A. The role of immunosenescence in the development of age-related diseases. Rev Invest Clin. 2016;68(2):84–91.
Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659–66.
Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31(2):578–85.
Littman A. Potent acid reduction and risk of enteric infection. Lancet. 1990;335(8683):222.
Sarker SA, Gyr K. Non-immunological defence mechanisms of the gut. Gut. 1992;33(7):987–93.
Kim JJ, Khan WI. Goblet cells and mucins: role in innate defence in enteric infections. Pathogens. 2013;2(1):55–70.
Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A, et al. The mucus and mucins of the goblet cells and enterocytes provide the first defence line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 2014;260(1):8–20.
Waldum HL, Hauso O, Fossmark R. The regulation of gastric acid secretion—clinical perspectives. Acta Physiol (Oxf). 2014;210(2):239–56.
Koelz HR. Gastric acid in vertebrates. Scand J Gastroenterol Suppl. 1992;193:2–6.
Johansson ME, Sjovall H, Hansson GC. The gastrointestinal mucus system in health and disease. Nat Rev Gastroenterol Hepatol. 2013;10(6):352–61.
Schubert ML. Gastric secretion. Curr Opin Gastroenterol. 2014;30(6):578–82.
Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28(1):96–107.
Hunt RH. The protective role of gastric acid. Scand J Gastroenterol Suppl. 1988;146:34–9.
Beasley DE, Koltz AM, Lambert JE, Fierer N, Dunn RR. The evolution of stomach acidity and its relevance to the human microbiome. PLoS One. 2015;10(7):e0134116.
Smith JL. The role of gastric acid in preventing foodborne disease and how bacteria overcome acid conditions. J Food Prot. 2003;66(7):1292–303.
Hornick RB, Music SI, Wenzel R, Cash R, Libonati JP, Snyder MJ, et al. The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bull N Y Acad Med. 1971;47(10):1181–91.
Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JI, Robins-Browne RM, et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect Immun. 2008;76(2):639–45.
Monk BC, Mason AB, Abramochkin G, Haber JE, Seto-Young D, Perlin DS. The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta. 1995;1239(1):81–90.
Perlin DS, Seto-Young D, Monk BC. The plasma membrane H(+)-ATPase of fungi. A candidate drug target? Ann N Y Acad Sci. 1997;3(834):609–17.
Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.
Nagata K, Satoh H, Iwahi T, Shimoyama T, Tamura T. Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicrob Agents Chemother. 1993;37(4):769–74.
Hirai M, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol. 1995;30(4):461–4.
Ajdic D, McShan WM, McLaughlin RE, Savic G, Chang J, Carson MB, et al. Genome sequence of Streptococcus mutans UA159, a cariogenic dental pathogen. Proc Natl Acad Sci USA. 2002;99(22):14434–9.
Monk BC, Mason AB, Kardos TB, Perlin DS. Targeting the fungal plasma membrane proton pump. Acta Biochim Pol. 1995;42(4):481–96.
Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33(5):617–21.
Ritter M, Schratzberger P, Rossmann H, Woll E, Seiler K, Seidler U, et al. Effect of inhibitors of Na+/H+exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes. Br J Pharmacol. 1998;124(4):627–38.
Capodicasa E, De Bellis F, Pelli MA. Effect of lansoprazole on human leukocyte function. Immunopharmacol Immunotoxicol. 1999;21(2):357–77.
Martins de Oliveira R, Antunes E, Pedrazzoli J Jr, Gambero A. The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res. 2007;56(3):105–11.
Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22(2):357–72.
Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.
Suzuki M, Mori M, Fukumura D, Suzuki H, Miura S, Ishii H. Omeprazole attenuates neutrophil-endothelial cell adhesive interaction induced by extracts of Helicobacter pylori. J Gastroenterol Hepatol. 1999;14(1):27–31.
Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996;382(1–2):189–92.
Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med. 1996;21(5):727–31.
Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol. 2005;11(26):4052–60.
Fornai M, Natale G, Colucci R, Tuccori M, Carazzina G, Antonioli L, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol. 2005;372(1):79–87.
Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006;71(9):1337–41.
Pastoris O, Verri M, Boschi F, Kastsiuchenka O, Balestra B, Pace F, et al. Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(4):421–9.
Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem. 2003;278(13):10993–1001.
Becker JC, Grosser N, Waltke C, Schulz S, Erdmann K, Domschke W, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun. 2006;345(3):1014–21.
Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44(8):1710–5.
Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55(11):476–80.
Namazi MR, Jowkar F. A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther. 2008;33(3):215–7.
Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, et al. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med. 2015;13:249.
Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Slaviero A, Shah NH, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128(8):845–53.
Liu W, Baker SS, Trinidad J, Burlingame AL, Baker RD, Forte JG, et al. Inhibition of lysosomal enzyme activities by proton pump inhibitors. J Gastroenterol. 2013;48(12):1343–52.
Sasaki T, Yamaya M, Yasuda H, Inoue D, Yamada M, Kubo H, et al. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol. 2005;509(2–3):201–10.
Kuroda M, Yoshida N, Ichikawa H, Takagi T, Okuda T, Naito Y, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med. 2006;17(1):89–93.
Aybay C, Imir T, Okur H. The effect of omeprazole on human natural killer cell activity. Gen Pharmacol. 1995;26(6):1413–8.
Shamburek RD, Ruddy S, Schubert ML. Omeprazole and neutrophil function. Gastroenterology. 1993;104(3):938–40.
Jiang S, Meadows J, Anderson SA, Mukkada AJ. Antileishmanial activity of the antiulcer agent omeprazole. Antimicrob Agents Chemother. 2002;46(8):2569–74.
Vishvakarma NK, Singh SM. Immunopotentiating effect of proton pump inhibitor pantoprazole in a lymphoma-bearing murine host: implication in antitumor activation of tumor-associated macrophages. Immunol Lett. 2010;134(1):83–92.
Vishvakarma NK, Singh SM. Augmentation of myelopoiesis in a murine host bearing a T cell lymphoma following in vivo administration of proton pump inhibitor pantoprazole. Biochimie. 2011;93(10):1786–96.
De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005;1(6):779–86.
Fais S. A nonmainstream approach against cancer. J Enzyme Inhib Med Chem. 2016;14:1–8.
Mehta J, Powles RL, Treleaven J, Shields M, Agrawal S, Rege K, et al. Cimetidine-induced myelosuppression after bone marrow transplantation. Leuk Lymphoma. 1994;13(1–2):179–81.
Ching TL, Koelemij JG, Bast A. The effect of histamine on the oxidative burst of HL60 cells before and after exposure to reactive oxygen species. Inflamm Res. 1995;44(3):99–104.
Ching TL, de Jong J, Bast A. Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid. Eur J Pharmacol. 1994;268(1):89–93.
Mikawa K, Akamatsu H, Nishina K, Shiga M, Maekawa N, Obara H, et al. The effects of cimetidine, ranitidine, and famotidine on human neutrophil functions. Anesth Analg. 1999;89(1):218–24.
Ciz M, Lojek A. Modulation of neutrophil oxidative burst via histamine receptors. Br J Pharmacol. 2013;170(1):17–22.
Werner K, Neumann D, Seifert R. Analysis of the histamine H2-receptor in human monocytes. Biochem Pharmacol. 2014;92(2):369–79.
Burde R, Seifert R. Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase. Naunyn Schmiedebergs Arch Pharmacol. 1996;353(2):123–9.
Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J Pharmacol. 2006;533(1–3):69–76.
Reher TM, Brunskole I, Neumann D, Seifert R. Evidence for ligand-specific conformations of the histamine H(2)-receptor in human eosinophils and neutrophils. Biochem Pharmacol. 2012;84(9):1174–85.
Nielsen HJ, Nielsen H, Moesgaard F, Tvede N, Klarlund K, Mansa B, et al. The effect of ranitidine on cellular immunity in patients with multiple myeloma. Cancer Immunol Immunother. 1990;32(3):201–5.
Nielsen HJ, Nielsen H, Jensen S, Moesgaard F. Ranitidine improves postoperative monocyte and neutrophil function. Arch Surg. 1994;129(3):309–15.
Neugebauer E, Lorenz W, Beckurts T, Maroske D, Merte H. Significance of histamine formation and release in the development of endotoxic shock: proof of current concepts by randomized controlled studies in rats. Rev Infect Dis. 1987;9 Suppl 5:S585–93.
Rixen D, Neugebauer E, Lechleuthner A, Buschauer A, Nagelschmidt M, Thoma S, et al. Beneficial effect of H2-agonism and H1-antagonism in rat endotoxic shock. Shock. 1994;2(1):47–52.
Hahm KB, Kim WH, Lee SI, Kang JK, Park IS. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol. 1995;30(3):265–71.
Nielsen HJ, Nielsen HI, Jensen S, Moesgaard FA. The effect of ranitidine on postoperative monocyte and neutrophil granulocyte function. Ugeskr Laeger. 1995;157(44):6119–24.
Rasmussen LA, Nielsen HJ, Sorensen S, Sorensen C, Rasmussen R, Sorensen S, et al. Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg. 1995;181(2):138–44.
Siegers CP, Andresen S, Keogh JP. Does cimetidine improve prospects for cancer patients?. A reappraisal of the evidence to date. Digestion. 1999;60(5):415–21.
Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol. 2010;161(4):755–67.
Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ. In vitro killing of nosocomial pathogens by acid and acidified nitrite. Antimicrob Agents Chemother. 2006;50(11):3901–4.
Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51(8):2883–7.
Wilson KH. Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol. 1983;18(4):1017–9.
Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175(7):745–8.
Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8.
Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.
Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56.
Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 2015;517(7533):205–8.
Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber GK, et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016;43(11):1142–53.
Clooney AG, Bernstein CN, Leslie WD, Vagianos K, Sargent M, Laserna-Mendieta EJ, et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016;43(9):974–84.
Melgar S, Nieuwdorp M. Are proton pump inhibitors affecting intestinal microbiota health? Gastroenterology. 2015;149(4):848–50.
Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient pH in Clostridium difficile: results of an in vitro study. J Med Microbiol. 2013;62(Pt 10):1517–23.
Hegarty JP, Sangster W, Harris LR 3rd, Stewart DB. Proton pump inhibitors induce changes in colonocyte gene expression that may affect Clostridium difficile infection. Surgery. 2014;156(4):972–8.
Craven DE, Driks MR. Nosocomial pneumonia in the intubated patient. Semin Respir Infect. 1987;2(1):20–33.
Atherton ST, White DJ. Stomach as source of bacteria colonising respiratory tract during artificial ventilation. Lancet. 1978;2(8097):968–9.
du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A. Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway. Lancet. 1982;1(8266):242–5.
Rosen R, Hu L, Amirault J, Khatwa U, Ward DV, Onderdonk A. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr. 2015;166(4):917–23.
de Jager CP, Wever PC, Gemen EF, van Oijen MG, van Gageldonk-Lafeber AB, Siersema PD, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther. 2012;36(10):941–9.
Schuijt TJ, Lankelma JM, Scicluna BP, de Sousa e Melo F, Roelofs JJ, de Boer JD, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut. 2016;65(4):575–83.
Lauderdale TL, Chang FY, Ben RJ, Yin HC, Ni YH, Tsai JW, et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med. 2005;99(9):1079–86.
Apisarnthanarak A, Mundy LM. Etiology of community-acquired pneumonia. Clin Chest Med. 2005;26(1):47–55.
Garcia-Martinez I, Frances R, Zapater P, Gimenez P, Gomez-Hurtado I, Moratalla A, et al. Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis. J Gastroenterol Hepatol. 2015;30(1):147–54.
Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29(7):1060–4.
Charlot M, Ahlehoff O, Norgaard ML, Jorgensen CH, Sorensen R, Abildstrom SZ, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med. 2010;153(6):378–86.
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.
Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.
Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64(1):9–13.
de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009;20(12):1989–98.
McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010;26(6):624–31.
Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, et al. Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011;23(9):794–800.
Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18 (quiz 19).
Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy. 2012;32(1):67–79.
Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, CaMos Research Group. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161–8.
Prieto-Alhambra D, Pages-Castella A, Wallace G, Javaid MK, Judge A, Nogues X, et al. Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. 2014;29(1):268–74.
Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185–202.
Cai D, Feng W, Jiang Q. Acid-suppressive medications and risk of fracture: an updated meta-analysis. Int J Clin Exp Med. 2015;8(6):8893–904.
Yang SD, Chen Q, Wei HK, Zhang F, Yang DL, Shen Y, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med. 2015;8(4):4899–910.
Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.
Andersen BN, Johansen PB, Abrahamsen B. Proton pump inhibitors and osteoporosis. Curr Opin Rheumatol. 2016;28(4):420–5.
Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA. 2007;297(13):1429 (author reply 30).
Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179(4):306–7.
Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med. 2011;171(11):998–1004.
O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.
Insogna KL. The effect of proton pump-inhibiting drugs on mineral metabolism. Am J Gastroenterol. 2009;104(Suppl 2):S2–4.
Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutr Rev. 2008;66(2):103–8.
Tawadrous D, Dixon S, Shariff SZ, Fleet J, Gandhi S, Jain AK, et al. Altered mental status in older adults with histamine2-receptor antagonists: a population-based study. Eur J Intern Med. 2014;25(8):701–9.
Otremba I, Wilczynski K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging. 2016;11:397–405.
Lundell L, Vieth M, Gibson F, Nagy P, Kahrilas PJ. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015;42(6):649–63.
Ko Y, Tang J, Sanagapalli S, Kim BS, Leong RW. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf. 2016;15(1):53–63.
Tran-Duy A, Spaetgens B, Hoes AW, de Wit NJ, Stehouwer CD. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(12):1706–19 e5.
Carnovale C, Gentili M, Fortino I, Merlino L, Clementi E, Radice S, et al. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme. Expert Opin Drug Saf. 2016;15(2):131–9.
Bertino JS Jr. The clopidogrel conundrum. J Clin Pharmacol. 2014;54(8):841–2.
Andersson T, Nagy P, Niazi M, Nylander S, Galbraith H, Ranjan S, et al. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. Am J Cardiovasc Drugs. 2014;14(3):217–27.
Hariharan S, Southworth MR, Madabushi R. Clopidogrel, CYP2C19 and proton pump inhibitors: what we know and what it means. J Clin Pharmacol. 2014;54(8):884–8.
Harvey A, Modak A, Dery U, Roy M, Rinfret S, Bertrand OF, et al. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity. J Breath Res. 2016;10(1):017104.
Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555–63.
Kim A, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY, et al. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos. 2014;42(7):1174–9.
Ding Y, Jia Y, Song Y, Lu C, Li Y, Chen M, et al. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects. Eur J Clin Pharmacol. 2014;70(2):141–6.
Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.
Santucci R, Leveque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 2010;30(9):3807–10.
Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014;78(3):565–71.
Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009;67(1):44–9.
Urai M, Kaneko Y, Niki M, Inoue M, Tanabe K, Umeyama T, et al. Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action. J Infect Chemother. 2014;20(10):612–5.
Knorr JP, Sjeime M, Braitman LE, Jawa P, Zaki R, Ortiz J. Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients. Transplantation. 2014;97(5):518–24.
Kees MG, Steinke T, Moritz S, Rupprecht K, Paulus EM, Kees F, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol. 2012;52(8):1265–72.
Kofler S, Wolf C, Shvets N, Sisic Z, Muller T, Behr J, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant. 2011;30(5):565–71.
Yamasaki M, Funakoshi S, Matsuda S, Imazu T, Takeda Y, Murakami T, et al. Interaction of magnesium oxide with gastric acid secretion inhibitors in clinical pharmacotherapy. Eur J Clin Pharmacol. 2014;70(8):921–4.
van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992–7.
Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf. 2016;15(2):223–36.
Matsuoka A, Takahashi N, Miura M, Niioka T, Kawakami K, Matsunaga T, et al. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70(2):351–2.
Takahashi N, Miura M, Niioka T, Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemother Pharmacol. 2012;69(4):999–1004.
Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.
Asaoka D, Nagahara A, Shimada Y, Matsumoto K, Ueyama H, Matsumoto K, et al. Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori? Ther Clin Risk Manag. 2015;11:381–91.
Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, et al. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14(13–14):647–60.
Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–9.
Gregoire JP, Moisan J, Chabot I, Gaudet M. Appropriateness of omeprazole prescribing in Quebec’s senior population. Can J Gastroenterol. 2000;14(8):676–80.
Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol. 2003;98(1):51–8.
van Vliet EP, Otten HJ, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20(7):608–12.
Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101(6):445–8.
van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther. 2009;29(5):571–9.
Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol. 2011;4(2):53–9.
Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, Boris L, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10(6):620–5 (quiz e57).
Haastrup PF, Rasmussen S, Hansen JM, Christensen RD, Sondergaard J, Jarbol DE. General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study. BMC Fam Pract. 2016;17(1):57.
Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol. 2000;95(11):3118–22.
Scagliarini R, Magnani E, Pratico A, Bocchini R, Sambo P, Pazzi P. Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice. Dig Dis Sci. 2005;50(12):2307–11.
Targownik LE, Metge C, Roos L, Leung S. The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol. 2007;102(5):942–50.
Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm. 2010;16(2):122–9.
Ramirez E, Lei SH, Borobia AM, Pinana E, Fudio S, Munoz R, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010;5(4):288–97.
Sheikh-Taha M, Alaeddine S, Nassif J. Use of acid suppressive therapy in hospitalized non-critically ill patients. World J Gastrointest Pharmacol Ther. 2012;3(6):93–6.
Patel HR, Dhande P. Imprudent gastro-protective approach in majority of specialists’ clinics of a tertiary hospital. J Clin Diagn Res. 2016;10(3):FC12–5.
Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207–11.
Shin S. Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: a retrospective chart review. Ther Clin Risk Manag. 2015;11:649–57.
Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200–5.
Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189–93.
Teramura-Gronblad M, Hosia-Randell H, Muurinen S, Pitkala K. Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents. Scand J Prim Health Care. 2010;28(3):154–9.
Patterson Burdsall D, Flores HC, Krueger J, Garretson S, Gorbien MJ, Iacch A, et al. Use of proton pump inhibitors with lack of diagnostic indications in 22 Midwestern US skilled nursing facilities. J Am Med Dir Assoc. 2013;14(6):429–32.
de Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, et al. Prevalence and associations of the use of proton-pump inhibitors in nursing homes: a cross-sectional study. J Am Med Dir Assoc. 2013;14(4):265–9.
Rane PP, Guha S, Chatterjee S, Aparasu RR. Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Res Social Adm Pharm. 2017;13(2):358–63.
Rababa M, Al-Ghassani AA, Kovach CR, Dyer EM. Proton pump inhibitors and the prescribing cascade. J Gerontol Nurs. 2016;42(4):23–31.
Haastrup PF, Paulsen MS, Christensen RD, Sondergaard J, Hansen JM, Jarbol DE. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther. 2016;44(1):78–87.
El-Serag HB, Fitzgerald S, Richardson P. The extent and determinants of prescribing and adherence with acid-reducing medications: a national claims database study. Am J Gastroenterol. 2009;104(9):2161–7.
van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Sociodemographic factors influence use of proton pump inhibitors among users of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2009;7(8):855–61.
Zhu LL, Xu LC, Chen Y, Zhou Q, Zeng S. Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications. World J Gastroenterol. 2012;18(24):3167–72.
Schiff M, Peura D. HZT-501 (DUEXIS((R)); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012;6(1):25–35.
Fujita T, Kutsumi H, Sanuki T, Hayakumo T, Azuma T. Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries. J Gastroenterol. 2013;48(5):559–73.
Schjerning Olsen AM, Gislason GH, McGettigan P, Fosbol E, Sorensen R, Hansen ML, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805–14.
Kim J, Lee J, Shin CM, Lee DH, Park BJ. Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population. BMJ Open Diabetes Res Care. 2015;3(1):e000133.
Yuan JQ, Tsoi KK, Yang M, Wang JY, Threapleton DE, Yang ZY, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262–75.
Yang M, He M, Zhao M, Zou B, Liu J, Luo LM, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017;25:1–8.
McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2):57–62.
Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35(8):976–83.
Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm. 2005;62(10 Suppl 2):S4–10.
Kurosawa S. What is important in treating elderly with H2 receptor antagonists. Nihon Rinsho. 2002;60(8):1613–7.
Lackner TE, Heard T, Glunz S, Gann N, Babington M, Malone DC. Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patients. J Am Geriatr Soc. 2003;51(5):650–6.
Manlucu J, Tonelli M, Ray JG, Papaioannou A, Youssef G, Thiessen-Philbrook HR, et al. Dose-reducing H2 receptor antagonists in the presence of low glomerular filtration rate: a systematic review of the evidence. Nephrol Dial Transplant. 2005;20(11):2376–84.
Boudville N. The predictable effect that renal failure has on H2 receptor antagonists–increasing the half-life along with increasing prescribing errors. Nephrol Dial Transplant. 2005;20(11):2315–7.
Matzke GR. Doses of histamine-2-receptor antagonists should be reduced in patients with low glomerular filtration rate. Nat Clin Pract Nephrol. 2006;2(6):298–9.
Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009;120(23):2310–2.
Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc. 2013;2(1):e004564.
O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–97.
Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624–41.
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–49.
Yamane K, Kato Y, Tazaki J, Tada T, Makiyama T, Imai M, et al. Effects of PPIs and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy. J Atheroscler Thromb. 2012;19(6):559–69.
Sherwood MW, Melloni C, Jones WS, Washam JB, Hasselblad V, Dolor RJ. Individual proton pump inhibitors and outcomes in patients with coronary artery disease on dual antiplatelet therapy: a systematic review. J Am Heart Assoc. 2015;4(11).
Wallace J, Paauw DS. Appropriate prescribing and important drug interactions in older adults. Med Clin N Am. 2015;99(2):295–310.
Jarchow-Macdonald AA, Mangoni AA. Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board. Geriatr Gerontol Int. 2013;13(4):1002–9.
Hershcovici T, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs. 2011;71(18):2381–9.
Huang J, Cao Y, Liao C, Wu L, Gao F. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Crit Care. 2010;14(5):R194.
Liu B, Liu S, Yin A, Siddiqi J. Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2015;19:409.
Krag M, Perner A, Wetterslev J, Moller MH. Stress ulcer prophylaxis in adult neurocritical care patients–no firm evidence for benefit or harm. Crit Care. 2016;20:22.
Ben-Menachem T, Fogel R, Patel RV, Touchette M, Zarowitz BJ, Hadzijahic N, et al. Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med. 1994;121(8):568–75.
Cook DJ, Reeve BK, Scholes LC. Histamine-2-receptor antagonists and antacids in the critically ill population: stress ulceration versus nosocomial pneumonia. Infect Control Hosp Epidemiol. 1994;15(7):437–42.
Patel AJ, Som R. What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors? Interact Cardiovasc Thorac Surg. 2013;16(3):356–60.
Krag M, Perner A, Wetterslev J, Wise MP, Hylander Moller M. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014;40(1):11–22.
Krag M, Perner A, Moller MH. Stress ulcer prophylaxis in the intensive care unit. Curr Opin Crit Care. 2016;22(2):186–90.
Buendgens L, Koch A, Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: risks and benefits of stress ulcer prophylaxis. World J Crit Care Med. 2016;5(1):57–64.
Martinez RC, Bedani R, Saad SM. Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. Br J Nutr. 2015;114(12):1993–2015.
Szajewska H, Konarska Z, Kolodziej M. probiotic bacterial and fungal strains: claims with evidence. Dig Dis. 2016;34(3):251–9.
Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J. 2004;80(947):516–26.
Islam J, Cohen J, Rajkumar C, Llewelyn MJ. Probiotics for the prevention and treatment of Clostridium difficile in older patients. Age Ageing. 2012;41(6):706–11.
Allen SJ. The potential of probiotics to prevent Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):135–44.
Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015;15(60 Suppl 2):S144–7.
Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;15(60 Suppl 2):S122–8.
McFarland LV. Probiotics for the primary and secondary prevention of C. difficile infections: a meta-analysis and systematic review. Antibiotics (Basel). 2015;4(2):160–78.
Auclair J, Frappier M, Millette M. Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): characterization, manufacture, mechanisms of action, and quality control of a specific probiotic combination for primary prevention of Clostridium difficile infection. Clin Infect Dis. 2015;15(60 Suppl 2):S135–43.
Ollech JE, Shen NT, Crawford CV, Ringel Y. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol. 2016;30(1):111–8.
Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.
Spinler JK, Ross CL, Savidge TC. Probiotics as adjunctive therapy for preventing Clostridium difficile infection—what are we waiting for? Anaerobe. 2016;41:51–7.
Chopra T, Goldstein EJ. Clostridium difficile infection in long-term care facilities: a call to action for antimicrobial stewardship. Clin Infect Dis. 2015;15(60 Suppl 2):S72–6.
Shen NT, Maw A, Tmanova LL, Pino A, Ancy K, Crawford CV, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017.
McFarland LV. Meta-analysis of probiotics for the prevention of traveler’s diarrhea. Travel Med Infect Dis. 2007;5(2):97–105.
Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis. 2015;13(2):128–34.
Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21(37):10644–53.
Compare D, Rocco A, Sgamato C, Coccoli P, Campo SM, Nazionale I, et al. Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. Dig Liver Dis. 2015;47(4):273–9.
Forsythe P. Probiotics and lung diseases. Chest. 2011;139(4):901–8.
Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015;2:CD006895.
Bo L, Li J, Tao T, Bai Y, Ye X, Hotchkiss RS, et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev. 2014;10:CD009066.
Zeng J, Wang CT, Zhang FS, Qi F, Wang SF, Ma S, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016;42(6):1018–28.
Vieira AT, Rocha VM, Tavares L, Garcia CC, Teixeira MM, Oliveira SC, et al. Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 5(1A). Microbes Infect. 2016;18(3):180–9.
Hanson L, VandeVusse L, Jerme M, Abad CL, Safdar N. Probiotics for treatment and prevention of urogenital infections in women: a systematic review. J Midwifery Womens Health. 2016;61(3):339–55.
Lytvyn L, Quach K, Banfield L, Johnston BC, Mertz D. Probiotics and synbiotics for the prevention of postoperative infections following abdominal surgery: a systematic review and meta-analysis of randomized controlled trials. J Hosp Infect. 2016;92(2):130–9.
Ohshima T, Kojima Y, Seneviratne CJ, Maeda N. Therapeutic application of synbiotics, a fusion of probiotics and prebiotics, and biogenics as a new concept for oral Candida infections: a mini review. Front Microbiol. 2016;7:10.
O’Connor EM. The role of gut microbiota in nutritional status. Curr Opin Clin Nutr Metab Care. 2013;16(5):509–16.
Mondot S, de Wouters T, Dore J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis. 2013;31(3–4):278–85.
Mondot S, Lepage P. The human gut microbiome and its dysfunctions through the meta-omics prism. Ann N Y Acad Sci. 2016;1372(1):9–19.
Lin CS, Chang CJ, Lu CC, Martel J, Ojcius DM, Ko YF, et al. Impact of the gut microbiota, prebiotics, and probiotics on human health and disease. Biomed J. 2014;37(5):259–68.
Tojo R, Suarez A, Clemente MG, de los Reyes-Gavilan CG, Margolles A, Gueimonde M, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J Gastroenterol. 2014;20(41):15163–76.
Cresci GA, Bawden E. Gut microbiome: what we do and don’t know. Nutr Clin Pract. 2015;30(6):734–46.
Peterson CT, Sharma V, Elmen L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015;179(3):363–77.
Spaiser SJ, Culpepper T, Nieves C Jr, Ukhanova M, Mai V, Percival SS, et al. Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 ingestion induces a less inflammatory cytokine profile and a potentially beneficial shift in gut microbiota in older adults: a randomized, double-blind, placebo-controlled, crossover study. J Am Coll Nutr. 2015;34(6):459–69.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137–50.
Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455.
Rogers GB, Keating DJ, Young RL, Wong ML, Licinio J, Wesselingh S. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol Psychiatry. 2016;21(6):738–48.
Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol. 2016;69(3):187–203.
Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell. 2010;140(6):859–70.
Chung H, Kasper DL. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Curr Opin Immunol. 2010;22(4):455–60.
Yu LC, Wang JT, Wei SC, Ni YH. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol. 2012;3(1):27–43.
Aziz Q, Dore J, Emmanuel A, Guarner F, Quigley EM. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil. 2013;25(1):4–15.
Valentini M, Piermattei A, Di Sante G, Migliara G, Delogu G, Ria F. Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells. J Immunol Res. 2014;2014:586939.
Medina M, Izquierdo E, Ennahar S, Sanz Y. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007;150(3):531–8.
Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr. 2014;54(7):938–56.
Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr. 2001;74(6):833–9.
Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG–host interactions. Microb Cell Fact. 2014;13(Suppl 1):S7.
Millette M, Dupont C, Archambault D, Lacroix M. Partial characterization of bacteriocins produced by human Lactococcus lactis and Pediococccus acidilactici isolates. J Appl Microbiol. 2007;102(1):274–82.
Zeinhom M, Tellez AM, Delcenserie V, El-Kholy AM, El-Shinawy SH, Griffiths MW. Yogurt containing bioactive molecules produced by Lactobacillus acidophilus La-5 exerts a protective effect against enterohemorrhagic Escherichia coli in mice. J Food Prot. 2012;75(10):1796–805.
Aoki T, Asahara T, Matsumoto K, Takada T, Chonan O, Nakamori K, et al. Effects of the continuous intake of a milk drink containing Lactobacillus casei strain Shirota on abdominal symptoms, fecal microbiota, and metabolites in gastrectomized subjects. Scand J Gastroenterol. 2014;49(5):552–63.
Pace F, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015;61(4):273–92.
Sugawara T, Sawada D, Ishida Y, Aihara K, Aoki Y, Takehara I, et al. Regulatory effect of paraprobiotic Lactobacillus gasseri CP2305 on gut environment and function. Microb Ecol Health Dis. 2016;27:30259.
Vlasova AN, Kandasamy S, Chattha KS, Rajashekara G, Saif LJ. Comparison of probiotic lactobacilli and bifidobacteria effects, immune responses and rotavirus vaccines and infection in different host species. Vet Immunol Immunopathol. 2016;172:72–84.
El-Abbadi NH, Dao MC, Meydani SN. Yogurt: role in healthy and active aging. Am J Clin Nutr. 2014;99(5 Suppl):1263S–70S.
Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.
Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7.
O’Connor EM, O’Herlihy EA, O’Toole PW. Gut microbiota in older subjects: variation, health consequences and dietary intervention prospects. Proc Nutr Soc. 2014;73(4):441–51.
Fisher A, Varendran R. Letter: clinical predictors of Clostridium difficile infection - advanced age and residential status are important factors for prediction and prevention. Aliment Pharmacol Ther. 2015;41(2):232–3.
Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64 (quiz 446–7).
Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;15(60 Suppl 2):S129–34.
Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36(6):775–80.
Bartley J. Vitamin D: emerging roles in infection and immunity. Expert Rev Anti Infect Ther. 2010;8(12):1359–69.
Hewison M. Vitamin D and innate and adaptive immunity. Vitam Horm. 2011;86:23–62.
White JH. Vitamin D metabolism and signaling in the immune system. Rev Endocr Metab Disord. 2012;13(1):21–9.
Gunville CF, Mourani PM, Ginde AA. The role of vitamin D in prevention and treatment of infection. Inflamm Allergy Drug Targets. 2013;12(4):239–45.
Quraishi SA, Litonjua AA, Moromizato T, Gibbons FK, Camargo CA Jr, Giovannucci E, et al. Association between prehospital vitamin D status and hospital-acquired bloodstream infections. Am J Clin Nutr. 2013;98(4):952–9.
de Haan K, Groeneveld AB, de Geus HR, Egal M, Struijs A. Vitamin D deficiency as a risk factor for infection, sepsis and mortality in the critically ill: systematic review and meta-analysis. Crit Care. 2014;18(6):660.
Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Krstic G, Wetterslev J, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database Syst Rev. 2014;6:CD007469.
Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2015;3(2):120–30.
Kempker JA, Magee MJ, Cegielski JP, Martin GS. Associations between vitamin D level and hospitalizations with and without an infection in a national cohort of medicare beneficiaries. Am J Epidemiol. 2016;183(10):920–9.
Sahay T, Ananthakrishnan AN. Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case–control study. BMC Infect Dis. 2014;14:661.
van der Wilden GM, Fagenholz PJ, Velmahos GC, Quraishi SA, Schipper IB, Camargo CA Jr. Vitamin D status and severity of Clostridium difficile infections: a prospective cohort study in hospitalized adults. JPEN J Parenter Enteral Nutr. 2015;39(4):465–70.
Abdelfatah M, Nayfe R, Moftakhar B, Nijim A, El Zoghbi M, Donskey CJ, et al. Low vitamin D level and impact on severity and recurrence of Clostridium difficile infections. J Investig Med. 2015;63(1):17–21.
Wong KK, Lee R, Watkins RR, Haller N. Prolonged Clostridium difficile infection may be associated with vitamin D deficiency. JPEN J Parenter Enteral Nutr. 2016;40(5):682–7.
Micic D, Rao K, Trindade BC, Walk ST, Chenoweth E, Jain R, et al. Serum 25-hydroxyvitamin D levels are not associated with adverse outcomes in Clostridium difficile infection. Infect Dis Rep. 2015;7(3):5979.
Ryz NR, Lochner A, Bhullar K, Ma C, Huang T, Bhinder G, et al. Dietary vitamin D3 deficiency alters intestinal mucosal defence and increases susceptibility to Citrobacter rodentium-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2015;309(9):G730–42.
Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA. 2012;308(13):1333–9.
Slow S, Priest PC, Chambers ST, Stewart AW, Jennings LC, Florkowski CM, et al. Effect of vitamin D3 supplementation on Staphylococcus aureus nasal carriage: a randomized, double-blind, placebo-controlled trial in healthy adults. Clin Microbiol Infect. 2014;20(5):453–8.
de Sa Del Fiol F, Barberato-Filho S, Lopes LC, de Cassia Bergamaschi C. Vitamin D and respiratory infections. J Infect Dev Ctries. 2015;9(4):355–61.
MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med. 2014;174(4):564–74.
Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.
Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The present review article was not funded.
Conflicts of interest
Leon Fisher and Alexander Fisher declare that they have no conflicts of interest to declare; they are not current or former employees of any pharmaceutical company and did not receive any financial support with regard to the content of this article.
Rights and permissions
About this article
Cite this article
Fisher, L., Fisher, A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 37, 587–624 (2017). https://doi.org/10.1007/s40261-017-0519-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-017-0519-y